Methods for Treating Acute Myeloid Leukemia

Genetically modified cells targeting the NF-κB pathway through gene deletion and ATP13A2 inhibition provide a novel therapeutic strategy for AML, reducing leukemic stem cell proliferation and improving survival rates.

JP2024544003APending Publication Date: 2024-11-26AGENCY FOR SCI TECH & RES
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024532885
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-01
Filing Date
2022-11-30
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Current treatments for acute myeloid leukemia (AML) face challenges with drug resistance and recurrence, necessitating the development of alternative therapeutic methods to improve remission rates and survival times.

Method used

Genetically modified cells with deleted genes p65(RELA), p50(NFKB1), p52(NFKB2), c-Rel(REL), and RelB(RELB) are used to modulate the NF-κB pathway, targeting ATP13A2 for treatment, combined with agents like chemotherapeutic agents, immunotherapeutic agents, and ATP13A2 inhibitors to reduce leukemic stem cell proliferation and mitochondrial dysfunction.

Benefits of technology

The approach effectively reduces leukemic stem cell proliferation, reverses mitochondrial dysfunction, and improves survival rates by targeting the NF-κB pathway, identifying ATP13A2 as a novel therapeutic target for AML.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544003000004
    Figure 2024544003000004
  • Figure 2024544003000005
    Figure 2024544003000005
  • Figure 2024544003000006
    Figure 2024544003000006
Patent Text Reader

Abstract

Provided is a genetically modified cell, in which at least one gene is deleted from the cell, and the gene is selected from the group consisting of p50, p52, p65, c-Rel, and RelB.Also disclosed is a method for identifying targets for treating acute myeloid leukemia (AML) in a subject, and a method for treating acute myeloid leukemia (AML) in a subject in need thereof, comprising inhibiting the activity of NF-KB pathway.Also provided is an ATP13A2 inhibitor for use in therapy or medicine, in treating AML, and in the manufacture of medicine for treating AML.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates broadly to methods for identifying therapeutic targets for treating acute myeloid leukemia (AML) using genetically modified cells and methods for treating AML. [Background technology]

[0002] Acute myeloid leukemia (AML) is a cancer of the blood cells of the myeloid system that causes rapid growth of abnormal cells in the bone marrow and blood, preventing the production of normal blood cells. AML progresses rapidly and is typically fatal within a few weeks or months if left untreated. AML affected approximately 1 million people worldwide in 2015, resulting in 147,000 deaths.

[0003] Remission-induction chemotherapy with cytarabine and anthracyclines has been the mainstay of AML treatment for the past 40 years, achieving complete remission (CR) in 60–80% of patients under the age of 60. However, 5-year overall survival (OS) for AML patients remains a challenge due to relapse, which has led to intense efforts to discover promising targeted therapies. Despite rapid advances in therapeutic approaches for acute myeloid leukemia (AML), first- and second-line drug resistance to current therapies remains a generalized problem, thus necessitating the identification and development of next-generation AML drugs, which could lead to the design of novel combination therapies to improve AML cure rates, prolong remission duration and survival, and improve the quality of life for AML patients.

[0004] Therefore, there is a need to provide alternative methods for treating AML. Summary of the Invention

[0005] In one aspect, a genetically modified cell is provided, wherein at least one gene has been deleted from the cell, the gene being selected from the group consisting of p65 (RELA), p50 (NFKB1), p52 (NFKB2), c-Rel (REL) and RelB (RELB).

[0006] In another aspect, a method of identifying a therapeutic target for treating acute myeloid leukemia (AML) in a subject is provided, the method comprising using a cell as described herein.

[0007] In yet another aspect, a method of treating acute myeloid leukemia (AML) in a subject in need thereof is provided, comprising modulating activity of the NF-κB pathway.

[0008] In some instances, perturbations in the NF-KB pathway regulate multiple pathways, including metabolic pathways, inflammatory pathways, cancer-related pathways, and combinations thereof.

[0009] In some examples, the NF-KB pathway gene is p65.

[0010] In some examples, the metabolic pathways include oxidative phosphorylation (OXPHOS), mitochondrial dysfunction, sirtuin signaling, and / or mTOR signaling.

[0011] In some examples, the cancer-associated pathway includes pathways associated with acute myeloid leukemia (AML), small lung cancer, and / or pancreatic adenocarcinoma, and optionally, the cancer-associated pathway includes AML and AML-associated signaling pathways including IL-6, IL-7, JAK, CXCR4, JAK-STAT, and / or GM-CSF.

[0012] In some examples, the inflammatory pathway includes TLR, TNFR2, CCL22, IL-10, IL-17A, CD40, and / or IL-6 signaling.

[0013] In some instances, the NF-KB pathway controls gene and / or protein expression of lysosome-associated proteins.

[0014] In some instances, the NF-KB pathway controls the function of lysosome-associated proteins.

[0015] In some instances, the gene for the lysosome-associated protein is ATP13A2. The respective protein is known as Park9.

[0016] In some examples, the methods include administering an agent that inhibits activity of the ATP13A2 gene.

[0017] In some examples, the treatment reduces one or more symptoms including decreased oxygen consumption rate (OCR), decreased mitochondrial maximal respiration, decreased mitochondrial spare respiratory capacity, decreased non-mitochondrial respiration, and combinations thereof.

[0018] In some instances, treatment reduces one or more symptoms, including decreased glycolysis, decreased glycolytic capacity, and combinations thereof.

[0019] In some instances, the treatment reverses or improves dysfunctional mitochondrial function.

[0020] In some instances, the treatment reduces one or more symptoms, including loss of ability of leukemic stem cells (LSCs) to proliferate and / or form colonies.

[0021] In some examples, the subject is further treated with an inhibitor, including a chemotherapeutic agent, an immunotherapeutic agent, a cellular therapeutic agent, an oligonucleotide, an antigen-binding molecule, a small molecule inhibitor, and / or a combination thereof.

[0022] In some examples, the subject is further treated with a chemotherapeutic agent.

[0023] In yet another aspect, there is provided an ATP13A2 inhibitor for use in therapy or medicine.

[0024] In yet another aspect, there is provided an ATP13A2 inhibitor for use in the treatment of AML.

[0025] In yet another aspect, there is provided the use of an ATP13A2 inhibitor in the manufacture of a medicament for treating AML.

[0026] definition The terms "treating," "treat," and "therapy," and their cognates, refer to both therapeutic treatment and prophylactic or preventative measures, the purpose of which is to prevent or slow (alleviate) a condition, including, but not limited to, a disease (such as acute myeloid leukemia / AML), a condition, or a disorder. A condition also includes the body's response to a disease or disorder, e.g., dysregulation of cell proliferation, dysregulation of cell metabolism, and / or inflammation. Subjects in need of such treatment include those already with a condition, as well as those susceptible to a condition or in whom a condition needs to be prevented.

[0027] The term "subject" as used herein includes patients and non-patients. The term "patient" refers to an individual who is suffering from or likely to suffer from a disease condition, such as acute myeloid leukemia / AML, while "non-patient" refers to an individual who is not suffering from or unlikely to suffer from a disease condition. "Non-patient" includes healthy individuals, non-diseased individuals, and / or individuals without a disease condition. "Subject" includes humans and animals. Animals include, but are not limited to, mammals (e.g., non-human primates, dogs, mice, etc.). "Mouse" refers to any mammalian member of the murine family, such as mice, rats, rabbits, etc. The term "micro" as used herein is broadly interpreted to include dimensions from about 1 micron to about 1000 microns.

[0028] The term "reverse" as used herein refers to reducing the symptoms caused by a disease, including reversing the damage caused by the disease and truly healing the body, or restoring vital cellular functions that have been blocked or affected by the disease or the like.

[0029] The term "ameliorate" as used herein refers to the act or process of making better the symptoms or prognosis of a disease, or a major cellular function.

[0030] As used herein, the term "nano" is broadly interpreted to include dimensions less than about 1000 nm.

[0031] The term "associated with" as used herein when referring to two elements refers to a broad relationship between the two elements. Relationships include, but are not limited to, physical, chemical, or biological relationships. For example, if element A is associated with element B, then element A and element B may be directly or indirectly attached to each other, or element A may contain element B, and vice versa.

[0032] The term "and / or," e.g., "X and / or Y," is understood to mean either "X and Y" or "X or Y," and is considered to explicitly support both meanings or either meaning.

[0033] Furthermore, in the detailed description herein, the term "substantially", whenever used, is understood to include, but is not limited to, "entirely" or "completely". Furthermore, terms such as "comprising", "comprise", and the like, whenever used, are intended to be open-ended descriptive language in that they broadly include the elements / components described after such terms, in addition to other components not expressly described. For example, when "comprising" is used, a reference to "a" feature is also intended to be a reference to "at least one" of that feature. Terms such as "consisting", "consist", and the like, may be considered as subsets of terms such as "comprising", "comprise", and the like, in the appropriate context. Thus, in embodiments disclosed herein that use terms such as "comprising", "comprise", and the like, it will be understood that these embodiments provide teachings for corresponding embodiments that use terms such as "consisting", "consist", and the like. Additionally, terms such as "about," "approximately," and the like, whenever used, typically refer to a reasonable variation, such as + / - 5% variation from the disclosed value, 4% variation from the disclosed value, 3% variation from the disclosed value, 2% variation from the disclosed value, or 1% variation from the disclosed value.

[0034] Furthermore, in the present description, specific values ​​may be disclosed in any range. The values ​​indicating the end points of the range are intended to indicate the preferred range. When a range is described, the range is intended to cover and teach not only all possible subranges but also each individual numerical value within the range. That is, the end points of the range should not be interpreted as inflexible limitations. For example, description of a range of 1% to 5% is intended to specifically disclose subranges such as 1% to 2%, 1% to 3%, 1% to 4%, 2% to 3%, etc., as well as to individually disclose values ​​within that range such as 1%, 2%, 3%, 4%, and 5%. It is to be understood that each individual numerical value within this range also includes integers, fractions, and decimals. Furthermore, whenever a range is described, the range is also intended to cover and teach values ​​from the indicated numerical endpoint to two additional decimal places or significant figures (if applicable). For example, a description of a range of 1% to 5% is intended to specifically disclose the ranges 1.00% to 5.00%, 1.0% to 5.0%, and all intermediate values ​​therein (such as 1.01%, 1.02%...4.98%, 4.99%, 5.00% and 1.1%, 1.2%...4.8%, 4.9%, 5.0%). The above specific disclosure intent is applicable to any depth / breadth of range.

[0035] Furthermore, when describing some embodiments, the present disclosure may disclose a method and / or process as a particular sequence of steps. However, it will be understood that unless specifically required, the method or process is not limited to the particular sequence of steps disclosed. Other sequences of steps may be possible. The particular order of steps disclosed herein should not be construed as unduly limiting. Unless specifically required, the method and / or process disclosed herein should not be limited to steps performed in the order described. The order of steps may vary and still be within the scope of the present disclosure.

[0036] Furthermore, while the present disclosure provides embodiments having one or more of the features / characteristics discussed herein, it will be understood that one or more of these features / characteristics may be abandoned in other alternative embodiments, and the present disclosure supports such abandonments and these related alternative embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0037] The NF-kB family of transcription factors (TFs) is represented by five canonical and non-canonical members: p65 (RELA), RelB (RELB), c-Rel (REL), p50 / p105 (NF-kB1), and p52 / p100 (NF-kB2). These TFs share a common Rel homology domain, which mediates their dimerization and their subsequent binding to functional DNA promoter elements, which results in downstream regulation of gene expression in a tissue- and context-dependent manner. NF-kB TFs bind to genomic regions in a homodimeric or heterodimeric manner and regulate diverse biological functions, including development, hematopoiesis, metabolism, immune function, etc., in a tightly regulated manner.

[0038] The NF-κB pathway is frequently deregulated in most hematological malignancies and can be directly driven by genetic mutations in relevant regulatory genes, such as in lymphoma and multiple myeloma (MM). These mutations can also drive acute myeloid leukemia (AML), a group of genetically heterogeneous clonal stem cell malignancies arising from leukemic stem cells (LSCs), which are pathogenic. Indeed, constitutive NF-κB pathway activation has been reported in 40% of AML patients, which has been shown to be indirectly driven by AML-associated genetic mutations. One frequently reported genetic driver of AML is the PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) gene fusion, which impairs myeloid differentiation and also inhibits the NF-kB pathway via p65. NF-kB TFs, and especially p65, have also been linked to metabolic reprogramming and adaptation in cancer. Furthermore, cytokine positive feedback loops and increased levels of an active proteasome machinery are also involved in constitutive NF-κB activity.

[0039] The past decade has seen extensive investigations focused on understanding the deregulation of the NF-κB pathway in hematological malignancies, which have led to the exploration of the clinical relevance of NF-kB inhibitors, which act primarily indirectly. Apart from the promising results of proteasome inhibitors in MM, which were indeed linked to the activation of the canonical NF-kB pathway, efforts to target this biology in other hematological malignancies have been less successful. This has raised concerns regarding the general strategy of global targeting of the NF-κB pathway, and calls for factor- and context-specific strategies to address the issues related to NF-κB pathway inhibition in the clinical setting. Much of the current understanding of the role of individual NF-κB family TFs in the development of AML is based on findings from biochemical assays, in vitro modeling, and animal studies, and the human-specific pathophysiological functions remain poorly understood at the molecular level. This calls for a more systematic examination of this biology to identify the specific roles of individual NF-kB TFs in the development of AML.

[0040] The opposing roles of NF-kB in cancer challenge common assumptions regarding its oncogenic properties, yet the human-specific pathophysiological functions of the NF-kB signaling pathway remain poorly understood. The inventors of the present disclosure utilized the deregulated NF-kB signaling pathway in AML as a probe to identify and characterize novel therapeutic targets. The inventors of the present disclosure systematically investigated the pathophysiological functions of individual NF-kB TFs in a human AML cell model (i.e., U937) by utilizing a novel oligomer-based dual gRNA CRISPR-Cas9-mediated knockout (KO) approach, where the inventors of the present disclosure generated U937 cells lacking individual NF-kB TFs: p50, p52, p65, c-Rel and RelB. Integration of global differential gene expression (DEG) data from five NF-kB TF KO cells identified TF-specific gene signatures. This TF-specific signature was combined with published NF-kB TF chromatin immunoprecipitation (ChIP) data to identify deregulation in cancer and metabolic pathway genes among p65 DEGs. Using metabolic and leukemia stem cell (LSC) proliferation analyses, as well as AML xenograft studies in humanized mice (hu-NOG), the inventors of the present disclosure showed that p65-deficient AML cells exhibited (i) deregulation of cellular bioenergetics, (ii) increased LSC properties, and (iii) enhanced pathogenesis in humanized NOG mouse xenografts. p65 -KO Classification of AML patients using a specific gene signature identified ATP13A2, a lysosomal transporter, as a predictive marker of patient treatment response and overall survival (OS). Impaired expression / inhibition of ATP13A2 in p65 KO is associated with (i) deregulation of cellular bioenergetic state and associated lysosomes, (ii) LSC properties, and (iii) p65 -KOThe present results support the anti-leukemic function of p65 linked to metabolic plasticity and elucidate the important role of ATP13A2 in human-associated AML pathology. Furthermore, the inventors demonstrated the function of LSCs in transforming into aggressive AML pathology, which is cellular energy adaptation via the p65-ATP13A2 axis.

[0041] Constitutive NF-kB activity observed in AML patients promotes NF-kB as a promising target for AML. However, clinical trials targeting NF-kB have not produced encouraging clinical results. The disclosed studies suggest p65-dependent stratification and provide ATP13A2 as a novel therapeutic target for AML. The present invention relates to the identification of novel therapeutic targets for AML, deciphered using gene signatures from pathologically aggressive NFkB-p65-deficient AML cell lines. When knocked down, ATP13A2, the top candidate gene of the gene signature, caused cellular energy adaptation and reversal of the aggressive phenotype of p65-deficient AML cells in a novel humanized mouse xenograft model. The disclosed findings suggest ATP13A2 as a novel therapeutic target for AML.

[0042] In one embodiment, a genetically modified cell is provided, wherein at least one gene is deleted (or knocked out) from the cell, and the gene is selected from the group consisting of p50 (NFKB1), p52 (NFKB2), p65 (RELA), c-Rel (REL) and RelB (RELB). In some examples, the genetic modification is based on CRISPR-Cas9. In some examples, a CRISPR-Cas9-based genetically modified cell as described herein is provided.

[0043] In some examples, a p50 knockout cell line is provided. In some examples, a p52 knockout cell line is provided. In some examples, a p65 knockout cell line is provided. In some examples, a c-Rel knockout cell line is provided. In some examples, a RelB knockout cell line is provided.

[0044] In some examples, the cell line can be a mammalian cell line. In some examples, the cell line can be a human cell line. In some examples, a genetically modified monocyte cell line is provided. In some examples, the cell can be a U937 cell. In some examples, a p50 knockout U937 cell line is provided. In some examples, a p52 knockout U937 cell line is provided. In some examples, a p65 knockout U937 cell line is provided. In some examples, a c-Rel knockout U937 cell line is provided. In some examples, a RelB knockout U937 cell line is provided.

[0045] In this disclosure, the inventors generated five knockout (KO) cell lines in the U937 background, such as p50-KO U937, p52-KO U937, p65-KO U937, Rel-KO U937, and RelB-KO U937.

[0046] In another aspect, a method for identifying a therapeutic target for treating acute myeloid leukemia (AML) is provided, the method comprising using a cell as described herein. In some examples, the cell can be one or more genetically modified knockout cells: p50-KO, p52-KO, p65-KO, cRel-KO, and / or RelB-KO.

[0047] In some examples, the present disclosure provides methods to find new AML targets using one or more genetically modified knockout cells: p50-KO, p52-KO, p65-KO, cRel-KO, and / or RelB-KO.

[0048] In some examples, the present disclosure provides methods to find novel AML targets using genetically modified knockout U937 cells: p50-KO U937, p52-KO U937, p65-KO U937, cRel-KO U937, RelB-KO U937.

[0049] In yet another aspect, there is provided a method of treating acute myeloid leukemia (AML) in a subject in need thereof, the method comprising modulating / activating / increasing / improving the activity or expression of the NF-κB pathway.

[0050] In various embodiments there is provided the use of an agent / composition capable of modulating / activating / increasing / improving the activity or expression of the NF-κB pathway in the manufacture of a medicament in the treatment of AML.

[0051] In various embodiments, methods are provided in which modulation / activation / increase / improvement of the NF-κB pathway modulates / regulates multiple pathways including metabolic pathways, inflammatory pathways, cancer-related pathways, and combinations thereof.

[0052] In various embodiments, a method is provided wherein the NF-κB pathway gene is p65.

[0053] In various embodiments, methods are provided in which the metabolic pathway includes, but is not limited to, oxidative phosphorylation (OXPHOS), mitochondrial dysfunction, sirtuin signaling, mTOR signaling, and the like.

[0054] In various embodiments, modulation / regulation (such as inhibition / decrease / reduction and / or increase / amplification) of a metabolic pathway is determined by methods known in the art.

[0055] In some examples, modulation / regulation (such as inhibition / decrease / reduction and / or increase / amplification) of metabolic pathways can be determined by measuring a bioenergetic profile.

[0056] In some examples, measurements of bioenergetic profiles include, but are not limited to, measurements of oxidative phosphorylation (OXPHOS), measurements of extracellular acidification rate (ECAR) for lactate production, measurements of glycolysis rates, measurements of mitochondrial metabolic rates, measurements of ATP production rates, and the like.

[0057] For example, oxidative phosphorylation is observed / analyzed / measured / determined by performing an assay to determine oxygen consumption rate (OCR). In some examples, OCR may be measured using an assay that determines / measures, but is not limited to, cellular respiration rate, mitochondrial function, etc. In some examples, OCR may be measured using an assay that determines but is not limited to, a mitostress assay, a Seahorse analyzer assay, an oxygen consumption rate assay kit, etc. In some examples, OCR is measured using a mitostress assay.

[0058] In some examples, glycolysis is observed / analyzed / measured / determined by performing an assay to determine lactate production (which can be analyzed / measured / determined via the extracellular acidification rate (ECAR)). In some examples, the ECAR can be measured using assays such as, but not limited to, a glycolytic stress assay, a SeahorseXF assay, a time-resolved fluorescence assay, etc. In some examples, the ECAR is measured using a glycolytic stress assay.

[0059] In various embodiments, methods are provided in which the cancer associated pathways include, but are not limited to, pathways associated with acute myeloid leukemia (AML), small lung cancer, pancreatic adenocarcinoma, and the like, and optionally the cancer associated pathways include, but are not limited to, AML and AML associated signaling pathways, such as IL-6, IL-7, JAK, CXCR4, JAK-STAT, GM-CSF, and the like.

[0060] In some examples, the AML-related pathology is associated with a number of markers, including but not limited to, CD244, CD123, CD117, CD45RA, SLCO2B1, SLC17A9, TCTN3, ULBP2, SLC43A1, CSF3R, CLEC7A, ABCA7, CD48, ATP13A2, SMAD3, SLC1A4, IL6R, HIST3H2A, PFDN2, SLC44A1, NACA, CPNE9, HECTD3, SLC30A5, RALGDS, CYCS, FHL2, PPIL3, CDKL5, GJB2, RPL6, RAB13, ADAMTS7, NDUFS4, HER2, HER3, HER4, HER5, HER6, HER7, HER8, HER9, HER1, HER2, HER1, HER2, HER1, HER2, HER3, HER4, HER5 ...2, HER1, HER2, HER2, HER3, HER4, HER2, HER1, HER2, HER2, HER3, HER4, HER4, HER5, HER2, HER2, HER3, HER4, HER5, HER2, Markers such as PUD2, GLG1, MTHFR, PSMA2, TNNT1, TMEM14A, MCTS1, PDCL3, RPSA, ARL3, INPP5B, RPLP0, IL19, ZER1, RPL10, RPS2, VCL, SKA2, GGCT, RPS4X, VPS25, MGST1, VPS29, BTF3, HMOX1, RPL5, TMEM60, EXOC3, IER3, AVL9, RIC8A, YWHAB, GTSF1, RPL8, SLC25A26, GPT2, TCIRG1, TIMM9, MSH5, ADA, SEC11C, TIMM8A, etc.

[0061] In some examples, the methods described herein are directed to the detection of CD244, CD123, CD117, CD45RA, SLCO2B1, SLC17A9, TCTN3, ULBP2, SLC43A1, CSF3R, CLEC7A, ABCA7, CD48, ATP13A2, SMAD3, SLC1A4, IL6R, HIST3H2A, PFDN2, SLC44A1, NACA, CPNE9, HECTD3, SLC30A5, RALGDS, CYCS, FHL2, PPIL3, CDKL5, GJB2, RPL6, RAB13, ADAMTS7, NDUFS4, HERPUD2, GLG1, MTHFR, PSM A2, TNNT1, TMEM14A, MCTS1, PDCL3, RPSA, ARL3, INPP5B, RPLP0, IL19, ZER1, RPL10, RPS2, VCL, SKA2, GGCT, RPS4X, VPS25, MGST1, VPS29, BTF3, HMOX1, RPL5, TMEM60, EXOC3, IER3, AVL9, RIC8A, YWHAB, GTSF1, RPL8, SLC25A26, GPT2, TCIRG1, TIMM9, MSH5, ADA, SEC11C, and TIMM8A.

[0062] In some examples, the method includes detecting and / or determining expression of one or more markers selected from the group consisting of ATP13A2, SMAD3, SLC1A4, IL6R, HIST3H2A, PFDN2, SLC44A1, NACA, CPNE9, HECTD3, SLC30A5, RALGDS, CYCS, FHL2, PPIL3, CDKL5, GJB2, RPL6, RAB13, ADAMTS7, NDUFS4, HERPUD2, GLG1, MTHFR, PSMA2, TNNT1, TMEM14A, and MCTS1.

[0063] In various embodiments, methods are provided in which the inflammatory pathway comprises TLR, TNFR2, CCL22, IL-10, CD40, IL-17A, PEDF, and / or IL-6 signaling.

[0064] In some examples, the methods may involve inflammatory pathways such as, but not limited to, TLR, TNFR2, IL-6, CCL22, IL-10, IL-17A.

[0065] In various embodiments, methods are provided for regulating / modulating (inhibiting / reducing / decreasing, etc.) gene / protein expression / levels of lysosome-associated proteins.

[0066] In some examples, methods of regulating / adjusting (inhibiting / reducing / reducing, etc.) the activity / expression / level of a lysosome-associated protein gene or protein may include, but are not limited to, the use of shRNA, siRNA, CRISPR-Cas9shRNA, knockdown using transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), inhibitors, drugs, etc. In some examples, gRNAs used in CRISPR-Cas9-mediated knockdown are listed in Table 1.

[0067] In some examples, lysosome-associated proteins may include, but are not limited to, lysosome-associated membrane proteins (e.g., LAMP1, LAMP2, LAMP3, etc.), ATP13A2 (Park9), lysosome integral membrane protein 2 (LIMP2), and the like.

[0068] In some examples, the methods may include downstream targets of lysosome-associated proteins (such as ATP13A2 / Park9), such as, but not limited to, TFEB, phosphorylated TFEB (such as ser-211), SYT11, alpha-synuclein, etc. In some examples, the downstream target of ATP13A2 (or Park9) is TFEB.

[0069] In various embodiments, methods are provided for modulating / regulating (inhibiting / reducing / decreasing, etc.) the function of a lysosome-associated protein.

[0070] In some examples, methods of regulating / modulating (e.g., inhibiting / reducing / reducing) the function of lysosome-associated proteins may include, but are not limited to, the use of drugs, inhibitors, antibodies and / or aptamers, chemical genetics, analog-sensitive enzyme alleles, chromophore-assisted laser inactivation, and the like.

[0071] In some examples, lysosomal function is measured by methods known in the art, including, but not limited to, analyzing lysosomal mass by determining / measuring / observing / analyzing lysosomal associated proteins and / or downstream targets, analyzing lysosomal acidification.

[0072] In some examples, lysosome-associated proteins and / or downstream targets of lysosome-associated proteins may be measured / observed / analyzed by flow cytometric analysis, western blot, quantitative analysis of microscopic (such as confocal) images, histological staining, gene expression, etc.

[0073] In some examples, lysosomal acidification can be analyzed by methods such as, but not limited to, staining with lysotracker, or using a ratiometric probe to measure lysosomal pH.

[0074] In various embodiments, methods are provided wherein the lysosome-associated protein is ATP13A2 (also known as PARK9).

[0075] In various embodiments, methods are provided that include administering an agent that modulates / inhibits / reduces / decreases the activity or expression of the ATP13A2 gene / mRNA / protein.

[0076] In some examples, reduction in AML pathology includes, but is not limited to, reduction / elimination / loss of leukemic stem cell (LSC) expansion / accumulation and / or proliferation, reduction in colony forming ability, reduction / elimination / reduction in induction of inflammatory proteins, reduction / elimination / reduction in pathological changes, increase in lysosomal mass and / or increase in lysosomal acidification, reversal of effects on normal hematopoiesis, reduction in leukemogenic cytokine signature, reversal of dysfunctional lymphoid immune compartment / lymphoid depletion in organs (such as the spleen), reduction in weight loss, improved survival, etc.

[0077] In some examples, the reduction / elimination / loss of LSC proliferation / expansion can be measured by methods known in the art, including but not limited to xenograft expansion assays, cell proliferation assays, and the like.

[0078] In some examples, the reduction / elimination / loss of LSC formation may be measured by methods known in the art, such as, but not limited to, colony forming unit assays, methylcellulose colony forming unit (CFU) assays (which determine the functional ability of cells to form LSC colonies).

[0079] In some examples, reduced induction of inflammatory proteins can include, but are not limited to, inflammatory proteins such as TNFα, IL-6, IL-1β, IL-18, IL-17a.

[0080] In some examples, pathological changes may include, but are not limited to, necrosis, cellularity in organs (bone marrow, spleen, etc.), apoptosis, etc. In some examples, necrosis may include, but is not limited to, deposition of amorphous granular eosinophilic material, hemorrhage, etc.

[0081] In some examples, cytokines and chemokines modulated in AML may include, but are not limited to, CCL22 (MDC), CCL3, CCL4, IL-10, IL-5, IL-8, IL-1β, PDGF-AA, CXCL1, CXCL2, CXCL3, CXCL9, CXCL10, CXCL12, etc. As shown in the experimental data of the present invention, the levels of tumor-promoting cytokines such as CCL22 (MDC) are increased, while the levels of anti-tumor cytokine IL-10 are decreased.

[0082] Without wishing to be bound by theory, it is believed that inhibition of the ATP13A2 pathway favorably modifies the energy status of tumor cells to maintain equilibrium.

[0083] In various embodiments, methods are provided in which the treatment reduces one or more symptoms, including, but not limited to, reduced / inhibited / reduced oxygen consumption rate (OCR), reduced / inhibited / reduced / reversed maximal / increased respiration, reduced / inhibited / reduced spare respiratory capacity, reduced / inhibited / reduced non-mitochondrial respiration.

[0084] In various embodiments, methods are provided in which the treatment reduces one or more symptoms, including, but not limited to, decreased / inhibited / reduced glycolysis, decreased / inhibited / reduced glycolytic capacity, decreased / inhibited / reduced / reversed mitochondrial respiration maximum / increase.

[0085] In various embodiments, methods are provided in which the treatment reverses / ameliorate mitochondrial dysfunction.

[0086] In various embodiments, methods are provided in which the treatment reduces one or more symptoms, including but not limited to, reduced / eliminated / diminished proliferation and / or colony forming ability.

[0087] In various embodiments, methods are provided wherein the subject is further treated with an inhibitor, such as a chemotherapeutic agent, an immunotherapeutic agent, a cellular therapeutic agent, an oligonucleotide, an antigen-binding molecule, a small molecule inhibitor, and / or a combination thereof.

[0088] In some examples, immunotherapeutic agents may include, but are not limited to, small molecules, monoclonal antibodies, checkpoint inhibitors, cytokines, vaccines, chimeric antigen receptor (CAR) T-cell therapy, and the like.

[0089] In some examples, cell therapy agents may include, but are not limited to, stem cell therapy, CAR T cell therapy, etc. In some examples, stem cell therapy may include, but is not limited to, the use of embryonic stem cells, tissue-specific stem cells, mesenchymal stem cells, induced pluripotent stem cells, etc.

[0090] In some examples, oligonucleotides can include, but are not limited to, small single stranded nucleic acids, antisense oligonucleotides, RNAi, therapeutic oligonucleotides, and the like.

[0091] In some examples, antigen-binding molecules may include, but are not limited to, antibodies, T cell receptors (TCRs), major histocompatibility complex (MHC) class I and class II antigens (MHC class I and MHC class II). In some examples, antibodies may include, but are not limited to, intracellular antibodies, extracellular antibodies, and the like.

[0092] In some examples, small molecule inhibitors may include, but are not limited to, tyrosine and serine / threonine kinase inhibitors, proteosome inhibitors, specific inhibitors of ATP13A2, and the like.

[0093] In some examples, inhibitors can reduce AML development through direct interaction with targets (such as ATP13A2, TFEB, etc.) and / or through indirect effects through deregulation of downstream components of the pathway (such as deregulated immunomodulatory cytokines / chemokines, etc.). In some examples, deregulated cytokines include, but are not limited to, MDC (CCL22), IL-10, IL1RA, PDGF-AA, FLT3-G, VEGF, etc.

[0094] In various embodiments, the methods include further treating the subject with a chemotherapeutic agent.

[0095] In various embodiments, chemotherapeutic agents may include, but are not limited to, gilteritinib, cytarabine, anthracyclines, venetoclax, glasdegib, ivosidenib, enasidenib, and the like.

[0096] In some aspects, an ATP13A2 inhibitor for use in therapy or medicine is provided.

[0097] In one aspect, an ATP13A2 inhibitor for use in the treatment of AML is provided.

[0098] In one aspect, there is provided the use of an ATP13A2 inhibitor in the manufacture of a medicament for treating a disease, such as AML.

[0099] In various embodiments, the method may include testing / evaluating the therapeutic potential of shRNA, siRNA, antisense oligonucleotides (ASO) in inhibiting ATP13A2 in AML. In some examples, antisense oligonucleotides may include, but are not limited to, small single-stranded nucleic acids with multiple chemical properties, etc., with clinical utility for multiple indications.

[0100] In various embodiments, methods may include designing ATP13A2-specific shRNA / ASOs in a gapmer configuration and / or testing the inhibitory effects on leukemia stem cell (LSC) function and metabolic adaptation of RelA-deficient AML cells.

[0101] In various embodiments, the method may include testing the most effective shRNA / ASO for off-target toxicity and immune response. In various embodiments, the present disclosure provides ASOs for off-target toxicity and immune response.

[0102] In various embodiments, the present disclosure provides ASOs for in vivo application to improve one or more of: hematopoiesis, induced pathological changes, and survival via inhibition of xenograft expansion in humanized mouse models.

[0103] In various embodiments, the method may include analyzing and validating the ASO that shows the best therapeutic effect in the CDX model in a humanized PDX model.

[0104] DNA constructs and cloning of paired guide RNAs (pgRNAs) in lentiviral vectors In some examples, a method of knocking out a gene from a cell line is provided. In some examples, the method includes introducing a pair of guide RNA (gRNA) cloning vectors and an expression vector into the cell line. In some examples, the expression vector can be a lentiviral expression vector. In some examples, the pair of gRNAs can include a set of reverse-complementary forward and reverse oligomers to target a gene of interest (e.g., targeting the NF-kB family of transcription factors). In some examples, the method of knocking out a gene from a cell line utilizes CRISPR-Cas9 technology.

[0105] In some examples, a method of knocking out a gene from a cell line is provided, the method being as described in Figure 1 A. In some examples, the disclosure includes an oligomer-based CRISPR-Cas9 approach to generate KO based on two sets of plasmids: a pair of gRNA cloning vectors (e.g., pAdaptor and pDonor) and an expression vector (e.g., a lentiviral expression vector, such as, but not limited to, PHASE-DEST-CAS9-T2A-GFP) (examples as shown in Figure 1A, Figure 18A and Figure 18B).

[0106] In some examples, for cloning of paired gRNAs into the pDonor vector, the method includes providing a set of reverse-complementary forward and reverse oligomers for each gRNA targeting the NF-kB family of transcription factors (TFs) synthesized from IDT™ (Integrated DNA Technologies™). In some examples, the oligomers can be about 20-30 bases long. In some examples, the oligomers can be about 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 bases long. In some examples, the oligomers can be 25 bases long. In some examples, as shown in Figure 1, the method includes first cloning pgRNAs into an adapter vector in a pool using gRNA-specific reverse-complementary forward and reverse primers (such as those shown in Table I), which involves equimolar mixing of the forward and reverse primers, phosphorylation, and then annealing and ligation to a bbsI-digested adapter (adapter + guide RNA pair) (Figure 1 and Figure 18A).

[0107] In some examples, the method includes pooling and purifying the adaptor-ligated pgRNA (e.g., by AMPure beads at a 1:1 ratio). In some examples, the method includes further ligating the pgRNA to an enzyme-digested donor plasmid (e.g., BbsI-digested pDonor), followed by transformation into host cells (such as with TOP10 cells) and plating on selection plates (such as kanamycin selection plates, as shown in FIG. 1A). In some examples, the method includes selecting bacterial clones that are at least 2x more, or 3x more, or 4x more, or 5x more (or more) than the paired guide RNA, and confirming the representation of the paired guide RNA in the pooled clones by sequencing (such as Sanger sequencing). In some examples, the method includes identifying the target-specific paired guide RNA based on sequencing (such as Sanger sequencing). In some examples, the method further includes efficiently shuttle the guide RNA into a DEST containing a lentiviral CAS9 expression plasmid using an LR Gateway reaction, as required by the experiment (as shown in FIG. 1A, FIG. 18B).

[0108] Lentivirus production, infection, and knockout In some examples, the method includes generating viral particles by co-transfecting a plasmid (such as a lentivirus expression plasmid containing paired gRNA and wild-type CAS9, dCAS9 derivative) with other plasmids (such as packaging plasmids) in a cell line (such as a Lenti-X cell line) using a transfection reagent (such as Xfect polymer) in a cell culture plate (such as a 6-well plate). In some examples, the method includes collecting the viral supernatant after transfection (such as 72 hours after transfection), filtering using a filter (such as a 0.45 μm filter), and then concentrating using a concentrator (such as a LentiX concentrator). In some examples, the method includes introducing a concentration of viral particles (such as a multiplicity of infection (MOI) of 10) into cells in the presence of a cationic polymer (such as polybrene, 2200 g for 1 hour, 22° C.). In some examples, the method includes cloning (e.g., single cell cloning) to identify clones (e.g., productive knockout clones) after infection (e.g., 5 days after infection), where cells are sorted directly into a cell culture plate (e.g., a round-bottom 96-well plate) using a fluorescent protein (e.g., constitutively expressed GFP). In some examples, the method includes expanding the clones (e.g., single cell clones) for 2 weeks, transferring cells (e.g., 90% expanded cells) from the cell culture plate (e.g., a 96-well plate) to a new cell culture plate (e.g., a V-shaped 96-well plate), pelleting by centrifugation, then dissolving the cell pellet with a buffer (e.g., 50 mM NaOH, 96°C for 30 minutes), and then neutralizing the buffer (e.g., NaOH) by addition of a buffer (e.g., 10% 1M Tris HCl pH 8.0). In some examples, the method includes centrifuging the cell culture plate (e.g., 4.5k for 5 minutes) and collecting the supernatant containing nucleic acid (e.g., genomic DNA) used for validation of the gene editing (e.g., by PCR amplification). In some examples, the methods include verifying the gene editing by amplifying and sequencing the target region using specific primer sets.In some examples, the method includes selecting clones (such as a minimum of two clones) with editing for each target gene based on sequencing (such as Sanger sequencing) and verifying loss at the protein level (e.g., using Western blotting).

[0109] Detection of TLR stimulation and cytokines In some examples, the method includes culturing the cells in a medium (such as RPMI) supplemented with serum (e.g., 10% FCS), amino acids (e.g., glutamine), antibiotics (e.g., penicillin, streptomycin), and salts (e.g., sodium pyruvate). In some examples, the method includes seeding the cells in a cell culture plate (such as two sets of 12-well plates) on the day of protein stimulation (such as TLR stimulation) and allowing them to rest (e.g., for 2 hours). In some examples, the method includes stimulating the cells with a bacterial component (e.g., LPS, after 2 hours). In some examples, the method includes lysing the cells in the first set after protein stimulation (e.g., 6 hours after LPS stimulation) in a chemical solution (e.g., Trizol) for nucleic acid (e.g., RNA) isolation, performing a second set of stimulation (e.g., 24 hours), collecting the supernatant, and analyzing the cytokines induced by the protein (LPS-induced cytokines: IL-6, IL1-β, etc.) using a kit (e.g., Ready-SET-GoElisaKit).

[0110] RNA-sequencing data analysis In some examples, the method includes assessing reads obtained from sequencing (such as Illumina sequencing) for quality using software (such as FASTQC version 0.11.7). In some examples, the method includes using software (such as Salmon version 0.11.3) for quantification of transcript abundance from paired-end reads (such as quasi-mapping based quantification), where a reference set of human transcripts is obtained from software (such as Gencode version 29). In some examples, the method includes summarizing transcript-level counts generated by the software (such as Salmon) into gene-level counts using software (such as tximport R / Bioconductor package version 1.2.3). In some examples, the method includes importing gene counts into software (such as DESeq2) for analysis of differentially expressed genes (DEGs). In some examples, the method includes fitting a model (such as a negative binomial generalized linear model (GLM)) to the count data including coefficients to model the effects of tissue type, treatment, and sample batch. In some examples, the method includes estimating parameters (such as size coefficients, dispersion parameters, etc.) in a model (such as GLM) from the count data. In some examples, the method includes adjusting the counts by any method (such as median ratio method) to normalize the size of the library. In some examples, the method includes performing a test (such as Wald test) on the model coefficients to identify DEGs. In some examples, the method includes selecting DEGs that meet the criteria of nominal p-value < 0.1 (such as nominal p-value < 0.005), at least 1.5 fold change, and baseMean > 10. In some examples, the method includes analyzing biological pathways and functions enriched in the DEGs using software (such as Ingenuity Pathway Analysis (IPA)). In some examples, the method includes writing custom scripts in software (such as R) to perform analyses (such as Principal Component Analysis (PCA)) and analyze correlations between samples.In some examples, the method includes expressing normalized gene abundance as reads (e.g., log transformed transcripts per million mapped reads, log2(TPM+1.0)), where a pseudocount value (e.g., 1.0) is added to prevent negative values, and using only genes with a baseMean above a value (e.g., 10) and with a gene ID (e.g., Entrez gene ID) and gene name. In some examples, the method includes using software (e.g., R package FactoMineR) for the analysis (e.g., PCA) and another software (e.g., pheatmap) for drawing the heatmap. In some examples, the method includes using a function (e.g., cor.test function) of the software (e.g., R base library) to evaluate correlation of samples by statistical methods (e.g., Spearman's correlation).

[0111] Analysis of ChIP-ChIP Data from Studies Known in the Art In some examples, the method includes analyzing the binding of transcription factors (such as NF-kB transcription factors) to promoters of differentially expressed genes by obtaining data from a previous ChIP-ChIP experiment (such as NF-kBChIP-ChIP) on U937 cells from a database (such as ArrayExpress) with accession ID (#E-WMIT-6). In some examples, the method includes processing raw data (such as raw two-color microarray data) using software (such as the marray Bioconductor package in R) to perform background correction and normalization (such as intra-array normalization) by any method (such as the loess method). In some examples, the method includes normalizing the resulting signal intensity across all arrays in the dataset (such as quartile normalization). In some examples, the method includes calculating the final signal intensity (e.g., final ChIP signal intensity) as the average of multiple samples (such as triplicates). In some examples, the method includes an assessment (e.g., metabolic assessment) by analysis (e.g., extracellular flux analysis): analysis of rates (e.g., oxygen consumption rate (OCR), and extracellular acidification rate (ECAR)). In some examples, the method includes hydrating a plate (e.g., utility plate) with sterile water (e.g., overnight, 37° C., in a non-CO2 incubator). In some examples, the method includes incubating a tube (e.g., Falcon tube) containing a buffer (e.g., calibration buffer) (e.g., overnight, 37° C., in a non-CO2 incubator). In some examples, the method includes seeding cells (e.g., U937 control and p65-KO cells) in a cell culture plate (e.g., a 6-well plate) the next day (e.g., 6 hours), and measuring the rates (e.g., OCR and ECAR) after incubation (e.g., after 6 hours) using an instrument (e.g., an XFp analyzer). In some examples, the method includes seeding cells (such as U937 control cells and p65-KO cells) onto a polymer-coated (such as poly-L-lysine coated) cell culture plate (such as an XFpSeahorse plate).In some examples, the method includes replacing the cell culture medium with a medium (such as XF basal medium) supplemented with amino acids (such as 2 mM glutamine (Gln), 11 mM glycolate (Glc)) and a compound (such as 2 mM pyruvate (Pyr)) with an adjusted pH (such as pH 7.4). In some examples, the method includes incubating the cells (such as for 1 hour at 37° C. and 5% CO2). In some examples, the method includes injecting a compound (such as 1.5 μM oligomycin, p-trifluoromethoxyphenylhydrazone (FCCP, 0.5 μM), and a mixture of antimycin A (0.5 μM) and rotenone (0.5 μM)) from a kit (such as the XFp Cell Mitostress Test Kit) during the assay. In some examples, the method includes reflecting the spare respiratory capacity or maximum respiratory rate of the cells that can be reached by an increase in rate (such as OCR) after application of the compound (such as FCCP). In some examples, the method includes verifying the rate (e.g., ECAR rate) by application of a test kit (e.g., glycolysis stress test kit). In some examples, the method includes supplementing the test kit assay medium (e.g., glycolysis stress test kit assay medium) with an amino acid (e.g., 2 mM Gln). In some examples, the method includes adding a drug (e.g., 1 μM oligomycin) after manual injection of a sugar (e.g., 10 mM glucose) followed by addition of another drug (e.g., 50 mM 2-deoxyglucose). In some examples, the method includes correlating an increase in the rate (e.g., ECAR) with a higher rate (e.g., glycolysis rate) by injection of a sugar (e.g., glucose) into the medium (e.g., previously glucose-free medium). In some examples, the method includes calculating the capacity (e.g., glycolysis capacity) of the cells, which is the maximum rate (e.g., maximum glycolysis rate) that can be achieved after application of the drug (e.g., oligomycin). In some examples, the method includes using software (e.g., Agilent Seahorse Software Wave 2.3) for data analysis.In some examples, the method includes using assay result data from the test (e.g., the Seahorse XF Cell Mitostress Test) to generate a test report (e.g., a Seahorse XF Cell Energy Phenotype Test Report) via a report generator (e.g., the Wave2.3 Report Generator).

[0112] Methylcellulose Human Colony Forming Unit (CFU) Assay In some examples, the method includes transferring media (such as MethoCult Optimized Media without EPO) from freezer temperature (such as -20°C) to refrigerator temperature (such as 2-8°C) the day before plating cells for an assay (such as a CFU assay). In some examples, the method includes seeding cells (such as U937 control and p65- / - cells in complete media) into each well of a cell culture plate (such as a 12-well plate) (such as for 6 hours). In some examples, the method includes washing and resuspending the cells in wash media (such as IMDM with 25mM HEPES) to create a more concentrated cell suspension (such as a 10x cell suspension) for untreated cells after incubation (such as for 6 hours incubation) or stimulating with a cytokine (such as IL-6, 12 hours) and then washing and resuspending in wash media (such as IMDM with 25mM HEPES) to create a more concentrated cell suspension (such as a 10x cell suspension). In some examples, the method includes vigorously shaking the thawed medium (e.g., MethoCult medium) (e.g., for 1-2 minutes), then leaving until all bubbles rise to the top (e.g., for at least 5 minutes), and then dispensing. In some examples, the method includes using a needle (e.g., a 16-gauge blunt-tip needle) to prepare medium aliquots (e.g., 14 mL Methocult medium aliquots). In some examples, the method includes adding a cell suspension (e.g., 100 μl (500 or 1000 cells) of cell suspension / plate) directly to a pre-dispensed tube of complete medium (e.g., MethoCult medium) and gently mixing to create a homogenous cell suspension. In some examples, the method includes plating the cell suspension in medium (e.g., MethoCult) in duplicate (e.g., in triplicate) into dishes (e.g., 35 mm dishes) for each clone (e.g., KO clone) and incubating (e.g., for 10 days at 37° C., 5% CO2, and 95% humidity or higher). In some instances, the method involves scanning the colonies using an instrument (such as an EVOSM7000) and counting them manually.

[0113] shRNA knockdown In some examples, the method includes performing a knockdown of a protein (such as ATP13A2) in cells (such as U937 cells and p65-KO cells) using a knockdown strategy (such as a pLKO-based shRNA strategy) transduced using a vector (such as a lentiviral shRNA pLKO vector as shown in FIG. 16A). In some examples, the method includes selecting the transduced cells with an antibiotic (such as 1 g / ml puromycin for 10 days). In some examples, the method includes verifying the efficiency of the knockdown (such as shRNA knockdown) using nucleic acid isolation (such as qPCR RNA isolation) and a quantitative amplification reaction (such as qRT-PCR). In some examples, the method includes isolating nucleic acid (such as total mRNA) from the cells using a kit (such as RNeasy Mini Kit (Qiagen)) and reverse transcribing according to the manual instructions. In some examples, the method includes performing an amplification reaction (such as real-time PCR) using nucleic acid (such as cDNA) and oligonucleotide primers in an instrument (such as an AB Biosystem 7000). In some examples, the methods include using the amplification reaction conditions of an instrument (such as a LightCycler) (2 min, 50°C, and 10 min, 95°C, followed by 40 cycles of 15 sec, 95°C, and 1 min, 60°C in a 15 μl reaction).

[0114] AML xenograft trials In some examples, the method includes performing a xenograft experiment (such as an AML xenograft experiment). In some examples, the method includes sublethally irradiating (such as X-ray irradiation (1.2 Gy)) the animals (such as 4-6 week old NOG mice) prior to transplantation (such as 2 days prior). In some examples, the method includes sublethally irradiating (such as X-ray irradiation (1.2 Gy) the cells (such as GFP+CTR cells and p65 -KOIn some examples, the method includes injecting humanized cells (e.g., U937 cells) into an animal (e.g., a mouse) via an organ (e.g., a tail vein) in any amount of buffer (e.g., PBS). In some examples, the method includes generating a humanized animal (e.g., a humanized NOG mouse) by sublethally irradiating (e.g., X-ray irradiation (1.2 Gy)) the animal (e.g., a 7-8 week old NOG mouse) and then injecting (e.g., tail vein injection) human blood (e.g., CD34+ human umbilical cord blood) derived from stem cells (e.g., hematopoietic stem cells (HSC)) / animal (e.g., a mouse) into the organ (e.g., a tail vein injection). In some examples, the method includes confirming successful engraftment by analysis (e.g., flow cytometry analysis) of cells (e.g., hCD45+ vs. mCD45+) in the blood (e.g., peripheral blood) at different time points after human stem cell transplantation (e.g., 4, 8, and 12 weeks after human HSC transplantation). In some examples, the method includes sublethally irradiating the animal (such as a mouse) after human stem cell transplantation (such as 12-14 weeks after human HSC transplantation) and after injecting the cells (such as U937 cells) (such as 2 days) as described for the xenograft (such as a NOG xenograft). In some examples, the method includes recording the weight of the animal (such as a mouse) daily. In some examples, the method includes collecting blood (such as peripheral blood after cell injection (such as 5-7 days and 11-16 days after AML cell injection)) from any region of the animal (such as the retro orbital sinus) using a tube (such as a heparinized capillary tube) for xenograft analysis. In some examples, the method includes collecting a sample (such as bone marrow) at an endpoint. In some examples, the method includes performing a phenotypic analysis of the xenograft in the sample (such as blood and bone marrow).

[0115] p65-p65 dimer regulated gene survival analysis in AML datasets In some examples, the method includes obtaining data (such as gene expression and survival data) from a database (such as cBioPortal) for the dataset (such as the AML datasets TARGET and TCGA). In some examples, the method includes selecting only patients who received standard chemotherapy (such as standard chemotherapy without BM transplant), and further excluding samples (such as PML-RAR samples) from the analysis due to their interaction with a transcription factor (such as p65). In some examples, the method includes performing an analysis (such as a univariate Cox regression analysis) on genes regulated by the transcription factor (such as genes regulated by p65) in each of the datasets (such as each of the two datasets). In some examples, the method includes performing an analysis (such as a random effects model meta-analysis) of proportions (such as hazard ratios) to obtain a composite proportion (such as a composite hazard ratio) represented as a plot (such as a forest plot). In some examples, the method includes an analysis (such as a meta-analysis) that reveals a list of genes (such as 29 genes) from which a panel of all possible genes (such as 3, 4 genes) was constructed. In some examples, the method includes using each of the panels in an analysis (such as a multivariate Cox regression analysis) for each of the datasets (such as the three datasets) to determine the predictive performance of the panels as indicated by their likelihood statistics (such as a proportion test P-value). In some examples, the method includes ranking the panels using results from the datasets (such as the three datasets) using a statistical method (such as a rank sum method) and a combined statistic (such as a combined P-value) calculated using a statistical method (such as the Fisher method). In some examples, the method includes performing the analysis using software (such as R version 3.6.2) using packages (such as the survival package and the metaphor package) for statistical analysis (such as Cox regression analysis) and analysis of proportions (such as a meta-analysis of hazard ratios).

[0116] result Functional delineation of NF-κB-TFs identified p65-mediated repression of genes associated with metabolic plasticity and cancer pathways.

[0117] The NF-κB family of transcription factors (TFs) exert their cellular and pathological functions through transcriptional regulation of a diverse set of target genes. Using U937 as an AML human cell model, the inventors of this disclosure systematically and comprehensively examined the cellular and pathophysiological functions of NFκB TFs in AML development. All five NF-kB family TF genes; p50 (NFKB1), p52 (NFKB2), p65 (RELA), c-Rel (REL), and RelB (RELB) were knocked out from the AML cell line U937 using the established CRISPR-Cas9 approach (Figure 1A) and specific gRNAs (Table I). [Table 1]

[0118] Figures 8A-8C show validation of CRISPR / Cas9KO of NF-kB TFs. A total of 11 independent validated KO clones (Figure 1), representing each of the five NF-kB TFs (i.e., p50, p52, p65, c-Rel, RelB), were then evaluated for potential loss of biological function by analysis of LPS-mediated induction of inflammatory proteins (Figures 8A-8C). Upon LPS stimulation, the inventors of the present disclosure found impairment in LPS-induced expression of secreted IL-6 and IL-1β proteins in all KO clones of p50, p52, p65 and c-Rel compared to unedited cells (CRISPR-Cas9 targeted without any editing, control, CTR) (Figure 1B). As expected, neither effect was observed in the RelB-KO clone (Figure 1B). Overall, this indicates that the NF-kB TF KO clones lost not only the targeted TF protein ( Fig. 8C ) but also the associated biological functions.

[0119] To gain mechanistic insight into the factor-specific functions of individual NF-kB TFs in AML pathology, we performed RNA-seq on untreated and LPS-treated CTR (n=3 clones) and KO cells, p50 -KO (n=2 clones), p52 -KO (n=2 clones), p65 -KO (n=3 clones), c-Rel -KO (n=2 clones), and RelB -KO A total of 28 samples (n=2 clones) were sequenced (Figure 1C, left panel). In total, 548.4 million paired-end 2x150bp reads were obtained by Illumina sequencing of mRNA extracted from these samples, with a median of 19 million reads per sample. Of all sequenced reads, 94.8% (519.8 million) were ≥ q30 on the Phread scale, and 87.3% (478.9 million) were mapped to known human transcripts. After obtaining the read counts across genes, 12,845 genes were selected that were annotated with unique Entrez gene IDs and gene names, were well expressed within the detection limit, and had an average of at least 10 read counts per sample after median library size ratio normalization. The inventors of the present disclosure performed a principal component analysis (PCA) of the expression profiles of all 28 samples represented by these 12,845 genes (Figure 1C, right panel). Samples plotted on the PC1 and PC2 axes are p65 -KO Clones and RelB -KO We showed distinct clusters of clones, indicating their unique properties compared to other NF-kB TF KOs, which remained prominent in the context of proinflammatory LPS treatment ( Fig. 1C , right panel).

[0120] To better understand potential factor-specific identities, the inventors of the present disclosure performed differential gene expression (DEG) analysis using DESeq2 contrasting NF-kB KO vs. CTR cells and LPS-treated vs. untreated cells (Figure 9). A total of 430 genes were found to be regulated by LPS treatment in CTR or NF-kB KO subclones based on p-value < 0.005 and greater than 1.5-fold change in expression (Figure 1D, Figure 10). More genes were found to be regulated by LPS treatment in individual NF-kB KO (c-Rel -KO , 50 genes, p50 -KO , 52 gene; p52 -KO , 50 genes; p65 -KO , 36 genes; RelB -KO NF-kB KO was upregulated by LPS in CTR cells (263 DEGs) more than that seen in CTR cells (124 genes), suggesting an impaired inflammatory response in NF-kB KO. Spearman's correlation analysis between the 14 LPS-treated samples showed that, based on these 430 DEGs, independent clones of the same NF-kB TF KO clustered together and therefore shared the highest correlation (Figure 1F). Furthermore, there were two major clusters, one for p65 -KO , p50 -KO , c-Rel -KO , p52 -KO , which consisted of KO clones, and the other was RelB -KO The RelB and CTR cells represent the canonical and non-canonical aspects of the NF-κB pathway, respectively. -KO The close correlation between RelB and CTR cells suggests a minor role for RelB in LPS-induced inflammation, consistent with previous reports. Ingenuity pathway analysis (IPA) of 430 DEGs in WT and F-kB KO cells revealed that p50 induced activation of inflammatory pathways, including TLR, TNFR2, and IL-6 signaling, in response to LPS. -KO , p52 -KO , p65 -KO , and c-Rel -KO The cells showed a marked loss of potency (Fig. 1G). In contrast, RelB -KOIn cells, inflammatory pathways were only moderately affected and responded in a manner roughly similar to that seen in CTR cells.

[0121] Since the main objective of the present disclosure was to investigate the pathophysiological function of NF-kB TFs in AML, the present disclosure inventors identified gene signatures specific to p50, p52, p65, c-Rel and RelB TFs by comparing the gene expression profiles of NF-kB KO cells and CTR cells in a steady-state unstimulated state (Figure 1E). A total of 1258 DEGs were obtained based on p-value < 0.005 and more than 1.5-fold change in expression. Analysis of Spearman correlation among 14 untreated samples based on 1258 DEGs showed that independent clones of the same knockout clustered together with high correlation (Figure 1H). Two broad clusters were observed, the first one was CTR, p50 -KO , p52 -KO , and c-Rel -KO cells, and the second one contains p65-KO and RelB -KO The p65 in unstimulated cells was composed of -KO and RelB -KO The clustering of DEGs may be due to the previously described functional interaction between p65 and RelB. IPA analysis of DEGs in different NF-kB KO cells showed enrichment of two main categories of pathways—metabolism (including oxidative phosphorylation, mitochondrial dysfunction, sirtuin and mTOR signaling) and cancer (including acute myeloid leukemia, small lung cancer and pancreatic adenocarcinoma signaling)-related pathways (Figure 1I). These pathways were associated with p65 -KO were over-represented in cells with positive Z-score values ​​(Figure 1I). Taken together, global gene expression analysis of the NF-kB KO human AML cell line U937 suggests state-specific homogeneity and heterogeneity in transcriptional regulation by NF-kB family TFs.

[0122] A disorganized p65-specific regulatory network leads to metabolic plasticity Regulation of gene expression by NF-kB TFs can occur by direct binding to target DNA regions or in an indirect manner. Figures 2A-2I show that NFkB-p65 deficiency promotes metabolic adaptation in AML cells. To identify direct targets of NF-kB in the dataset of 1258 DEGs from this disclosure (steady state, Figure 1E), the inventors of this disclosure crossed this list with the art-known ChIP-ChIP NF-kB binding profile described in U937 cells (Figure 2A, left panel). This identified 595 genes that are direct targets of NF-kB TFs. These 595 genes were clustered into a total of 22 gene modules (>5 genes / cluster, Figure 2A, right panel) that suggest they are directly regulated by NF-κB homodimers or heterodimers. Among these modules, two p65 / p65 homodimer-specific modules (total of 225 genes, with 138 downregulated and 87 upregulated genes, respectively) appeared to be the most prominent (Figure 2A, right panel). These 225 genes were further analyzed for pathway enrichment by IPA. Metabolic and cancer-related pathways were identified as the most prominently altered, further reinforcing the suggested role of p65 homodimer in controlling key aspects of metabolism and cancer (Figure 2B). The most enriched pathways included oxidative phosphorylation (OXPHOS), sirtuin signaling pathway, and mitochondrial dysfunction (Figure 2B), which was further highlighted by the differential regulation of genes involved in these pathways in p65-KO cells compared to CTR and other NF-kB KO cells (Figure 2C). Compared to CTR and other NF-κB KO cells, the enrichment of metabolic pathways in p65-KO AML cells was primarily due to downregulation of genes involved in these pathways in p65-KO cells (Figure 2C). Importantly, ChIP-ChIP NF-kB binding profiles showed specific binding of p65 within the genomic loci of these deregulated metabolic genes (Figure 2D, lower panel, examples shown for AKT1 and COX6A1). p65 binding at these loci was consistent with p65 -KOThis inversely correlated with RNA-seq read coverage (gene expression) in U937 cells (Figures 2C, 2D), suggesting p65-mediated regulation of these metabolic pathways in U937 AML cells.

[0123] The inventors of the present disclosure next sought to determine whether the predicted deregulation of metabolic pathways in p65-KO cells could result in demonstrable metabolic perturbations. To this end, the inventors of the present disclosure used CTR clones and p65 -KO The bioenergetic profile of the clones was measured. The oxygen consumption rate (OCR), an indicator of OXPHOS, and the extracellular acidification rate (ECAR), an indicator of glycolysis, were measured using mitochondrial and glycolytic stress assays, respectively. Compared to CTR, p65 -KO Clones showed an overall increased OCR and ECAR levels, suggesting deregulated metabolic function in the absence of p65 (Figures 2E, 2G, data for all clones combined). Importantly, all p65-KO clones showed significantly increased basal OCR (p=0.03) compared to CTR clones, which was linked to increased proton leak, since no changes were observed in ATP synthesis (Figure 2F). p65-KO cells also showed increased maximal respiration (p=0.02), spare respiratory capacity (p=0.02, in response to FCCP stress), and non-mitochondrial respiration (p=0.03) (Figure 2F). Analysis by glycolytic stress assays revealed that p65, compared to CTR clones, was significantly increased basal OCR (p=0.03), which was linked to increased proton leak, since no changes were observed in ATP synthesis (Figure 2F). p65-KO cells also showed increased maximal respiration (p=0.02), spare respiratory capacity (p=0.02, in response to FCCP stress), and non-mitochondrial respiration (p=0.03) (Figure 2F). Analysis by glycolytic stress assays showed that p65, compared to CTR clones, was increased basal OCR (p=0.03), suggesting deregulated metabolic function in the absence of p65, compared to CTR clones (Figure 2E). -KO The clones showed increased glycolytic and glycolytic capacity, but no changes were observed in non-glycolytic acidification (Figure 2H). -KO Upregulation of both mitochondrial respiration and glycolysis in clones was associated with p65 -KOThis suggests a potential "hybrid" metabolic state in cells, which may be due to impaired cellular bioenergetics. This was supported by cellular energy phenotype analysis (Figure 2I). Taken together, our data in this disclosure suggest that (i) p65 links gene regulation and metabolic pathways, and (ii) p65-KO cells are in a "hybrid" metabolic state. This p65 metabolic plasticity allows U937 cells to adapt to hostile environments, which are often observed in cancer and may also be applicable in the context of AML development.

[0124] Loss of p65 aggravates induced AML pathology In addition to metabolic pathways, p65 homodimer-specific regulatory modules (225DEGs) / p65 -KO Cell-specific DEGs also showed enrichment of cancer-related pathways, including AML and AML-related signaling pathways (IL-6, IL-7, JAK, CXCR4, JAK-STAT, and GM-CSF signaling) (Figure 2B). Figures 3A-3L show the inhibition of AML progression mediated by the p65 gene regulatory network. Genes related to these AML-related pathways were significantly downregulated in p65 compared to CTR or other NF-kB KO cells. -KO The NF-kB binding profiles of p65 were highly deregulated in the U937 clones (Figure 3A). As detailed above, ChIP-ChIP NF-kB binding profiles showed specific binding of p65 within the genomic loci of these deregulated cancer-specific genes (Figure 11). p65 binding at these loci was consistent with p65 in U937. -KO We directly correlate RNA-seq read coverage (gene expression) in leukemia and demonstrate an association between decreased p65 absence and increased gene expression, suggesting a potential inhibitory role for homodimeric p65 in regulating leukemia-specific pathways, which is indeed consistent with previous reports showing its target-specific role in the context of transcriptional regulation.

[0125] AML is characterized by the uncontrolled expansion and accumulation of leukemic stem cells (LSCs). -KOSeeking to investigate whether the predicted deregulation of AML-associated pathways in cells could translate into demonstrable LSC function, the inventors of the present disclosure therefore examined the effect of p65 deletion on LSC formation by methylcellulose colony-forming unit (CFU) assay, which determines the functional ability of cells to form LSC colonies. All p65-deficient clones (N=5 clones) were found to have an improved ability to proliferate and form colonies compared to CTR (N=5) clones (Figure 3B), suggesting a negative role of p65 in LSC function. Taken together, this data strongly links p65-mediated energy metabolic plasticity and stemness programs in AML cells, suggesting an anti-leukemic effect of p65.

[0126] Figures 12A-12E show the specific anti-leukemic role of NFkB-p65 in an induced AML xenograft model in immunodeficient NOD / shi-scid-IL-2Rganull (NOG) mice. To further explore the potential "antileukemic" role of p65, the inventors of the present disclosure compared disease progression after injection of p65-KO and CTR unedited cells in the NOG xenograft mouse model (Figure 12A). As shown in Figure 12B, p65 -KO Xenografts, in contrast to CTR xenografts, showed severe weight loss and p65 -KO This suggests a more aggressive progression of xenografts. p65 -KO Weight loss in xenografts led to their lower survival rate compared to CTR xenografts (Figure 12C). Because the CRISPR-Cas9 edited clones used in this study can be easily tracked due to the constitutive expression of the fluorescent marker GFP, the inventors of this disclosure used flow cytometry to measure hCD45 expression in whole blood. + GFP + The expansion of xenografts was analyzed by detection of hCD45 in the periphery (FIG. 12D, left panel). + GFP + AML cells were significantly more abundant in p65-KO-injected NOG compared to CTR-injected NOG (FIG. 12D, right panel). -KOThe faster expansion of GFP+ AML cells in injected NOG also led to the progression of induced AML, i.e., p65-KO xenografts showed severe weight loss and reduced survival (Figure 12B). -KO , p52 -KO , c-Rel -KO , and RelB -KO were also analyzed for their role in AML development, and as shown in Figure 12E, no significant effect of their deficiency was observed on the survival rate of induced xenografts, suggesting a specific role for p65 in AML development.

[0127] Hematological malignancies, including AML, are characterized by perturbed progenitor cells leading to impaired differentiation and enhanced proliferation, which ultimately leads to bone marrow (BM) remodeling and failure of normal hematopoiesis. To investigate this, the inventors of the present disclosure next investigated the upregulation of p65 in an established humanized NOG (huNOG) xenograft model with normal human-like hematopoiesis. -KO Engraftment of the and CTR clones was analyzed (Figures 3C, 13A, and 13B). Figures 13A-13B show a U937-induced AML xenograft model in humanized immunodeficient (huNOG) mice. Consistent with the NOG xenograft data (Figures 12B, 12C, and 12D), p65 in huNOG mice was significantly increased. -KO Xenografts showed severe weight loss and poor overall survival compared to CTR xenografts (Figures 3C, 3D, and 3E). + GFP + The frequency of cells with p65 -KO and CTR huNOG xenografts appeared to progress, whereas p65 -KO The p65 expression level was significantly higher in the hNOG xenograft group (see also Figures 3F, 3G, and 12D). Xenograft expansion / infiltration in tissues; BM and spleen were also analyzed, as was blood, and p65 expression was significantly higher in the CTR xenograft group compared to the CTR xenograft. -KO Increased expansion of GFP+ AML cells in the BM and spleen of the xenografts was further demonstrated (Figure 3F, Figure 3H). -KOMarkers associated with AML development between xenografts and CTR xenografts; hCD45 in blood + GFP + No differences were found in the expression of CD244, CD123, CD117, and CD45RA on the cells (Figures 14A, 14B). Figures 14A-B show that the anti-leukemic function of p65-KO in induced AML development is independent of known LSC markers.

[0128] In huNOG mice, the inventors of the present disclosure found a significant inverse correlation between blood xenograft frequency and survival, i.e., higher xenograft frequency (p65 -KO We observed a significant correlation between survival and humanization prior to xenograft injection (chimerism prior to xenograft injection) (Figure 3I). However, no significant correlation was observed when comparing survival with humanization prior to xenograft injection (chimerism prior to xenograft injection) (Figure 3J). To further understand the impact of p65 deficiency on AML development in the context of normal hematopoiesis, the inventors of the present disclosure investigated the expression of human leukocytes (hCD45 + The inventors of the present disclosure found that the frequency of p65 -KO Total hCD45 in the blood of xenografts + The frequency of hCD45 was significantly decreased, suggesting that normal hematopoiesis was impaired (Fig. 3K). + GFP + (xenograft) and hCD45 + GFP - As shown in Figure 3L, an inverse correlation was observed, indicating that the progression of induced AML disease has a significant impact on normal hematopoiesis. However, the impairment of normal hematopoiesis was not observed in the control group, as was the case in the p65 -KO This is highly evident in xenografts, which is due to the p65 -KOFurther suggesting the aggressive nature of AML cells (Figure 3L). Taken together, the data disclosed herein suggest an anti-leukemic role for p65, and reduction of p65 has an impact on normal hematopoiesis through a competitive advantage of p65-KO AML cells, supporting previous observations in the hematopoietic compartment of RelA / p65-deficient mice.

[0129] p65-KO-specific deregulated genes represent novel therapeutic targets for AML development Since p65-deficient AML exhibits a disturbed gene signature, which leads to enhanced metabolic adaptation, LSC function, and xenograft growth, resulting in reduced survival of p65KO-induced AML xenografts, the inventors of the present disclosure next explored whether the p65 dimer-specific gene signature (441 genes, Fig. 1E) identified in U937 AML cells could be used as a prognostic predictor to unearth novel targets of clinical relevance in AML patients. Figures 4A-I show that using the p65-KO gene signature as a probe, we identified ATP13A2 as a prognostic marker for AML. A total of 374 of the 441 genes were consistently detected at the mRNA level in the two AML datasets analyzed; TCGA (The Cancer Genome ATLAS) and TARGET (Therapeutically Applicable Research to Generate Effective Treatments) (Fig. 4A, left panel F). Analysis of these 374 genes by univariate Cox regression models revealed that 25 genes in TCGA (PDCL3, ATP13A2, ARL3, INPP5B, TNNT1, ZER1, SMAD3, CDKL5, VCL, GGCT, CPNE9, MGST1, VPS29, HIST3H2A, HERPUD2, TMEM60, CYCS, PPIL3, FHL2, AVL9, RIC8A, PSMA2, MTHFR, ADAMTS7, TIMM8A) and 32 genes in TARGET (RPSA, RPLP0, RPSA, RPLP1, RPLP2, RPLP3, RPLP4, RPLP5, RPLP6, RPLP7, RPLP8, RPLP9, RPLP1, RPLP2, RPLP1, RPLP2, RPLP3, RPLP1, RPLP2, RPLP1, RPLP2, RPLP3, RPLP1, RPLP2, RPLP3, RPLP4, RPLP1, RPLP2, RPLP1, RPLP2, RPLP1, RPLP2, RPLP3 ... We identified several datasets (IL19, SLC1A4, RPL10, RPS2, RPL6, SKA2, RPS4X, VPS25, SLC44A1, BTF3, IL6R, TNNT1, HMOX1, PFDN2, RALGDS, RPL5, EXOC3, RAB13, IER3, YWHAB, GTSF1, RPL8, SLC25A26, GPT2, TCIRG1, TMEM14A, TIMM9, MSH5, ADA, and SEC11C) that were significantly associated with risk of or prevention from AML.Further meta-analysis combining the TCGA and TARGET results identified 28 genes significantly associated with either risk or protection in both the TARGET and TCGA cohorts (Figure 4A, right panel). These genes were ATP13A2, SMAD3, SLC1A4, IL6R, HIST3H2A, PFDN2, SLC44A1, NACA, CPNE9, HECTD3, SLC30A5, RALGDS, CYCS, FHL2, PPIL3, CDKL5, GJB2, RPL6, RAB13, ADAMTS7, NDUFS4, HERPUD2, GLG1, MTHFR, PSMA2, TNNT1, TMEM14A, and MCTS1.

[0130] Forest plots summarizing HR and CI for the top gene ATP13A2 also identified a significant improvement in survival in AML patients in both datasets, as shown in Figure 4B, 4C. Furthermore, Cox regression analysis was performed to identify robust 3-4 gene marker combinations among the identified 28 candidates for better prediction of overall survival (Figure 15). Patient stratification based on 3- and 4-gene signature models further improved prediction of overall survival in both AML cohorts (Figure 15). Notably, ATP13A2 remained the top gene signature, followed by p65 -KO This further suggests its important molecular role in the aggressive AML pathology associated with p65. ATP13A2 encodes the PARK9 protein, a transmembrane lysosomal P5-type transport ATPase, which was upregulated in p65-KO AML cells (Figure 4A). ATP13A2 expression was associated with AML patient survival in two datasets (hazard ratio 0.59, Figure 4B).

[0131] To investigate the therapeutic relevance of ATP13A2, the inventors of the present disclosure used shRNA technology to suppress the expression of ATP13A2 in p65-KO AML cells (p65-KO-shATP13A2-1) to levels comparable to those observed in CTR cells (Figure 16A, Figure 16B). These shRNAs were knocked down and tested for LSC function using a CFU assay (Figure 4D). As shown in Figure 4D, p65 -KO cells (p65 -KO The reduction in ATP13A2 expression in the -shATP13A2 mice was associated with p65 -KO This results in a loss of LSC proliferation and colony formation capacity that is enhanced in association with

[0132] The inventors of the present disclosure then -KO Impaired expression of ATP13A2 in induced xenografts -KO We analyzed whether the tumor-associated aggressive AML development was also affected by the xenograft [control (n=10), p65 -KO (n=10), and p65 -KO -shATP13A2 (n=10)] was induced and disease progression was analyzed (Figure 4E). Xenograft expansion was analyzed in 50% of mice on day 13 by flow cytometry of blood, bone marrow, and spleen. As expected, p65 -KO The xenograft expansion in the IL-16 group was significantly higher in the blood, BM, and spleen compared to the control group, whereas p65 -KO Decreased ATP13A2 expression in cells correlates with p65 expression in blood and spleen. -KO The aggressive expansion / invasion of p65 was completely reversed in the BM, whereas a moderate reversal was observed in the BM (Figure 4F). -KO Aggressive p65 in tissues compared to -shATP13A2 -KO Consistent with xenograft expansion, p65 -KO Xenografts showed poor survival, which was attributed to the p65 -KO -shATP13A2 xenografts (Fig. 4G). This further indicates that ATP13A2-driven p65 -KOThis suggests the aggressive nature of AML.

[0133] Further histological evaluation using H&E demonstrated that all three groups (control, p65 -KO , and p65 -KO -shATP13A2) revealed AML cell infiltration, which was significantly higher than that in the control group and p65 -KO -p65 -KO This appeared to be more pronounced in animals from the 50-mg group. -KO Decreased expression of ATP13A2 in cells correlates with increased p65 expression in the spleen. -KO -shATP13A2 significantly impaired cell invasion (Figure 4I, left panel), and p65 -KO A moderate decrease in the invasion of -shATP13A2 xenografts was observed (Figure 4H, left panel). This data was consistent with the flow cytometry analysis (Figure 4F). AML cell invasion and expansion also result in pathological changes. Therefore, a subjective scoring-based analysis (described in the Methods section) was applied to compare the invasion of control, p65 -KO , and p65 -KO We analyzed the pathological changes induced by -shATP13A2 xenografts. In general, infiltration of xenografts was significantly greater in the BM and spleen than in controls and p65 -KO -p65 than shATP13A2 -KO The most prominent pathological changes observed were necrosis in the BM and lymphocyte depletion in the spleen (Fig. 7A, 7B). Overall, the pathological changes were more prevalent in the p65+ xenografts than in the other two groups. -KO This was common in xenotransplants, but this was due to p65 -KO -shATP13A2 xenografts. Taken together, this suggests an ATP13A2-dependent aggressiveness of p65-KO AML cells.

[0134] ATP13A2 mediates p65-regulated metabolic adaptation in AML cells ATP13A2 mediates p65-associated metabolic adaptation. ATP13A2 is a lysosomal P5-type transport ATPase (PARK9) that has been found to play a key role in lysosomal function and mediate p65-KO-associated AML pathology. Therefore, the inventors of the present disclosure evaluated the impact of downregulating ATP13A2 expression in p65-KO cells on their lysosomal function. Similar to ATP13A2, the inventors of the present disclosure next used gene signature enrichment analysis (GSEA) to analyze whether loss of p65 in U937 AML cells also regulates other lysosomal genes, resulting in deregulation of gene expression of lysosomal-associated proteins. GSEA of expression data showed that p65 downregulates other lysosomal genes, resulting in deregulation of gene expression of lysosomal-associated proteins. -KO We revealed increased expression of multiple lysosomal genes in lysosomal cells, which appears to be mediated through TFEB, a known downstream target of ATP13A2 (Figure 5A,B,C). As shown in the left panel of Figure 5B, intracellular staining flow cytometry analysis of phosphorylation of TFEB at ser-211 revealed that it inhibited nuclear translocation and expression of its target genes by upregulating p65 -KO We found that p65-deficient cells were downregulated in ser-211, whereas total TFEB levels were increased (Fig. 5B, right panel). Consistent with the flow cytometry analysis, Western blotting further demonstrated downregulated ser-211, and the opposite for total TFEB levels, suggesting deregulation of TFEB-related functions in p65-deficient cells (Fig. 5C). Interestingly, p65 -KO Deregulation of TFEB in cells is indeed mediated through ATP13A2, because shRNA knockdown of ATP13A2 inhibits p65 -KO p65-KO AML cells showed a significant increase in lysosomal function, as ... well as a decrease in TFEB phosphorylation at ser-211 and total TFEB levels in p65-KO AML cells (Fig. 5B, C). This suggested a global deregulation of lysosomal function in p65-KO AML cells.

[0135] p65 -KOTo further investigate whether the deregulation of TFEB and upregulation of lysosomal gene expression in cells was also observed at the cellular level, the lysosomal membrane protein LAMP1 was analyzed as an indicator of lysosomal mass by flow cytometry and confocal microscopy. As shown in Figure 5D, increased LAMP1 expression was associated with increased p65 expression compared to the control group. -KO The cells were also stained for LAMP1 using confocal microscopy; control, p65 -KO , and p65 -KO A comprehensive and quantitative analysis of -shATP13A2 cells showed significantly increased p65 expression compared to controls. -KO We further demonstrated an ATP13A2-dependent increase in lysosomal mass in p65 cells with high levels of ATP13A2 (Figure 5E). ATP13A2 is also known to regulate lysosomal function through acidification, so cells were stained with the pH-sensitive dye lysotracker to analyze lysosomal acidification. -KO Cells showed increased lysosomal acidification compared to control cells, which was reversed in p65-KO-shATP13A2 cells (Figure 5F). -KO This suggests a deregulated lysosome-related function in cells, which is related to p65 -KO This is likely mediated through ATP13A2, as reducing ATP13A2 expression by shRNA knockdown in cells reverses the deregulated lysosomal pathway: mass and acidification.

[0136] Lysosomal function has been shown to affect cellular bioenergetics; therefore, the inventors of the present disclosure hypothesize that ATP13A2 is involved in the "hybrid" metabolic state of p65-KO cells (Figures 2E-I). Thus, expression of ATP13A2 reduced p65 -KO The cells were analyzed for their bioenergetic profile using mitochondrial and glycolytic stress assays, respectively. As expected, p65 -KOCells appeared to have higher OCR and ECAR compared to controls (Figure 5G-J). Analysis of global mitochondrial OXPHOS and glycolytic function parameters further suggested dysfunctional mitochondrial function, increased glycolytic function, and a hybrid bioenergetic state (Figure 5G-J, Figure 17). However, p65 -KO Decreased expression of ATP13A2 in cells is associated with increased expression of p65 -KO It reversed the overall bioenergetic profile associated with the cells, including increased mitochondrial (OCR) and glycolytic (ECAR) phenotypes (Figures 5G-5J, Figure 17).

[0137] To further demonstrate the importance of targeting ATP13A2 in AML, we knocked down ATP13A2 in U937 cells by shRNA and injected these cells into huNOG mice (Figure 5K, left panel). U937 cells transformed with scrambled shRNA (control) were injected into huNOG mice. huNOG mice xenografted with shATP13A2 U937 AML cells survived longer (Figure 5K, right panel).

[0138] Taken together, our data link the aggressive nature of p65-KO cells with deregulated lysosomal and metabolic functions in these cells and demonstrate the role of the endolysosomal transporter ATP13A2 in the pathology. Furthermore, we propose a novel p65-ATP13A2 axis that regulates metabolic adaptation through the coordination of lysosomal and bioenergetic pathways, which defines the pathophysiological nature of inducible AML disease progression and the overall survival of human AML patients. The inventors of this disclosure propose ATP13A2 as a potent novel target for AML therapy.

[0139] Aggressive p65-KO AML cells induce a pro-leukemogenic cytokine / chemokine signature upon xenografting in humanized mice The inventors of the present disclosure used a huNOG xenograft model and showed that the blood / spleen / bone marrow (BM) of huNOG mice that received p65-KO xenografts had more AML cells (Figure 3C-Figure 3H). Because cytokines and chemokines play an important role in the development of AML, either by directly promoting the proliferation of AML cells or by suppressing anti-tumor immune responses, the inventors of the present disclosure next analyzed human cytokines and chemokines (using multiplex ELISA) in serum from huNOG xenografts from the experiment in Figure 3C. The inventors of the present disclosure found that several human cytokines / chemokines, such as MDC (CCL22), IL-10, IL-5, IP-10, and PDGF-AA, were significantly upregulated in serum of p65-KO xenografts compared to huNOG mice that received control xenografts (Figure 6A). Notably, in p65-KO xenografts, CCL22 levels were increased, whereas IL-10 levels were decreased, which is known to be associated with the antitumor function of immune cells (Figure 6B). Collectively, these data suggest an anti-leukemic effect of p65, where reduction of p65 has an impact on normal hematopoiesis through a competitive advantage of p65-KO AML cells, and also induces a pro-leukemic cytokine signature in xenografts.

[0140] Targeting ATP13A2 in aggressive p65-KO AML cells reverses lymphodepletion and pro-leukemogenic cytokine / chemokine signatures in xenografts. Histopathological analysis of BM and spleen from huNOG mice showed significant changes in the overall pathology of xenografts induced by p65-KO AML cells compared to controls (Figure 4H, Figure 4I). This was found to be mediated through ATP13A2, as reducing the expression of ATP13A2 reversed the pathology of p65-KO AML cells (Figure 4H, Figure 4I). Further analysis of histopathological data revealed extensive necrosis in the BM of p65-KO xenografts compared to controls (Figure 7A). This necrosis was also associated with the deposition of amorphous granular eosinophilic material, often accompanied by hemorrhage (Figure 7A). Furthermore, the inventors of the present disclosure noted severe lymphodepletion (immunosuppression) in the spleens of p65-KO xenografts, indicating dysfunction of the lymphoid immune compartment, which has been shown to play a key role in tumor surveillance and antitumor function (Figure 7B). Interestingly, BM necrosis and splenic lymphoid depletion were reversed when ATP13A2 expression was reduced in p65-KO AML cells (Figure 7A,B). This data further supported the leukemogenic role of ATP13A2, which is involved not only in leukemic stem cell function but also in xenotransplantation-induced immune dysfunction.

[0141] Tumor-induced immunosuppression is associated with aggressive disease progression and resistance to treatment (chemotherapy, immunotherapy, and cell therapy), and may be induced by direct interaction or indirectly by deregulated immunoregulatory cytokines / chemokines. This is indeed also the case in the situation of immunosuppression (lymphocyte depletion) observed in xenografts induced by p65-KO AML cells (Figure 7B). Therefore, the inventors of the present disclosure next determined human cytokines / chemokines to further understand the role of ATP13A2 in AML pathology. In general, huNOG mice receiving ATP13A2-depleted p65KO AML cells showed a reduced inflammatory state (Figure 7C). Importantly, analytes such as CCL22, IL10, IL1RA, PDGF-AA, FLT3-G, and VEGF, known to be associated with AML pathology and reduced survival of AML patients, were found to be present at reduced concentrations in the serum of huNOG mice receiving ATP13A2-depleted p65-KO AML cells compared to huNOG mice receiving p65-KO AML cells (Figure 7D). This reversal coincided with the reversal of lymphocyte depletion. Collectively, the data disclosed herein link the aggressive nature of p65-KO cells to leukemogenic cytokine and chemokine signatures, as well as immune suppression driven via ATP13A2.

[0142] Enhanced NF-κB activity has been frequently observed in cancer, which is primarily considered to be a tumorigenic property. However, the opposing roles of NF-κB in cancer counter this assumption. Similarly, perturbations of the NF-κB pathway have also been reported in AML disease, but their human-specific pathophysiological functions remain poorly understood. Here, the inventors of this disclosure present a systematic and comprehensive cellular and pathophysiological function of NF-kB TFs in AML development using U937 as an AML cell model. The inventors of this disclosure first used a pgRNA-mediated CRISPR-Cas9 approach to knock out NF-kB TFs in U937 cells (Figure 1A, Figure 8). Global transcriptome analysis revealed the selective impact of deletion of NF-κB TFs on LPS-induced inflammatory genes in U937 cells (Figure 1C-Figure 1E). Contrasting effects of p65 and RelB deletion on gene expression in steady-state and inflammatory conditions (LPS-stimulated) were observed (Figure 1F-I), which may be due to the known inhibitory interaction of RelB and p65, as shown in previous studies known in the art.

[0143] Analysis of p65 dimer-specific target genes in unstimulated cells identified deregulation of metabolic signaling pathways in p65-deficient U937 AML cells, which correlated with a more energetic "hybrid" state characterized by an increase in both ECAR and OCR (Figure 2B, Figure 2C, Figure 2E-Figure 2I). Metabolic programming and plasticity are hallmarks of proliferative cancer tissues. Interestingly, genes linked to AML and common cancer pathways were also found to be deregulated in p65-KO AML cells (Figure 2B, Figure 3A). AML disease is characterized by uncontrolled proliferation and expansion of LSCs, which originate from bone marrow progenitors and are enhanced in p65-KO U937 cells. This supports previous reports showing expansion of progenitors in the BM, enhanced stemness, and tumor progression (Figure 3B). Notably, stemness is linked to upregulation of glycolysis, which is widely believed to be crucial for tumorigenesis. We have shown that aggressive p65-deficient U937 AML cells have a "hybrid" metabolic state with increased OCR and ECAR. This hybrid state may improve the ability of cancer cells to meet their bioenergetic and biosynthetic needs for growth and may also affect the potential response of cancer cells to therapeutic approaches. The aggressive hematologic, tissue expansion, pathological changes, and reduced viability induced by energetic p65-deficient U937 AML cells in immunodeficient and humanized xenograft mouse models further support the potential antileukemic function of p65 and were shown to occur at the expense of normal hematopoiesis (Figures 3C-L, 12).

[0144] To clarify the mechanism of pathologically aggressive p65KO AML cells, we used p65 / p65 dimer-specific differentially expressed genes to stratify human AML patients in both TCGA and TARGET cohorts. Stratification and univariate Cox regression analysis based on p65-specific gene signatures, followed by random-effects model meta-analysis of hazard ratios, identified 28 genes significantly associated with either risk or protection (Figure 4A). The p65 dimer-specific gene signature captured not only known prognostic and therapeutic markers (SLC1A4, IL6R, HECTD3, RALGDS, FHL2, MTHFR) but also less characterized markers, such as the top-ranked gene, ATP13A2. ATP13A2 showed an inverse correlation between its expression and overall survival (Figure 4B, Figure 4C), which indeed confirms the pathologically aggressive nature (increased ATP13A2 expression) of p65-KO AML cells in vitro or in an inducible xenograft model (Figure 3C-3L, Figure 12). Increased expression and tumor-promoting function of ATP13A2 have been reported in colon cancer and may be a novel prognostic / therapeutic biomarker. In line with the inverse correlation between ATP13A2 and overall survival in AML patients, p65 -KO Impairment of ATP13A2 expression in cells reversed the pathological features, further supporting its AML-promoting function (Figures 4D-I).

[0145] ATP13A2, which is p65-regulated in U937 cells, plays a key role in TFEB-mediated lysosomal homeostasis and function. -KO The enrichment of lysosomal genes and increased TFEB activation in cells indicate deregulated lysosomal homeostasis, which is related to the p65 -KOThis is supported by increased lysosomal mass and acidification in p65-deficient AML cells (Figure 5A, Figure 5D, Figure 5E). The deregulated lysosomal homeostasis in p65-deficient AML cells is mediated through ATP13A2, which is consistent with previous reports showing inhibition of TFEB activity and lysosomal dysfunction in cells lacking a functional APT13A2 gene in fibroblasts (Figure 5B, Figure 5C). Interestingly, increased lysosomal mass has been reported in AML compared to normal hematopoietic cells, which is consistent with our findings showing enhanced LSC function and aggressive nature of p65-deficient induced xenotransplantation. Furthermore, ATP13A2 mediates the upregulation of p65 -KO It may also be important for the high-energy metabolic properties of cells, as its reduced expression inhibits increased glycolysis and mitochondrial respiration, ultimately downregulating p65. -KO Because AML cells also lost their high-energy metabolic profile and pathological advantage (Figure 5F-5K). The findings in this disclosure suggest a novel p65-ATP13A2 axis that regulates metabolic adaptation by regulating lysosomal and bioenergetic pathways, which defines the pathophysiological nature of inducible AML disease progression and the overall survival of human AML patients. Nevertheless, the advanced bioenergetic metabolic state of p65-deficient AML cells not only renders the cells pathologically aggressive, but also more vulnerable to metabolic targeting agents currently being investigated or approved for clinical use. The inventors of this disclosure hypothesize that there may be at least two AML patient endotypes based on p65-NF-KB activity, which may be useful to hierarchically classify the metabolic heterogeneity, diversity, and dependency of AML patients, thus enhancing personalized treatment for AML patients, and also merits further research to better understand the clinical implications of the p65-ATP13A2 regulatory axis in AML pathology and response to therapy.

[0146] Overall, the disclosed studies identify state-specific homogeneity and heterogeneity in transcriptional regulation by dimers of NF-κB family TFs in human AML cell lines and establish the pathophysiological significance of p65 dimer-dependent control of energy metabolism for metabolic adaptation in AML, which defines a bioenergetic pathway controlled through ATP13A2 by which p65 can promote AML progression and survival.In addition, p65 dimer-specific gene signatures complement known and new prognostic and therapeutic targets, suggesting their therapeutic implications, as p65 dimer-dependent gene signatures may help to improve the exploitation of metabolic vulnerabilities for personalized therapy in AML.

[0147] material and method DNA constructs and cloning of paired guide RNA (pgRNA) in lentiviral vectors The oligomer-based pgRNA-CRISPR-Cas9 lentiviral approach for generating KOs is based on two sets of plasmids: paired gRNA cloning vectors (pAdaptor and pDonor) and a lentiviral expression vector (PHASE-DEST-CAS9-T2A-GFP) (Figure 1A).

[0148] For cloning of paired gRNAs into pDonor vector, a set of reverse-complementary forward and reverse 25-nt oligomers of each gRNA targeting NF-kB family TFs was synthesized from IDT. As shown in Figure 1, pgRNAs were first cloned in pools into the adapter vector using gRNA-specific reverse-complementary forward and reverse primers (Table I). This involves equimolar mixing of forward and reverse primers, phosphorylation, followed by annealing, and ligation to bbsI-digested adapters (adapter + guide RNA pairs). The adapter-ligated pgRNAs were then pooled, purified by AMPure beads in a 1:1 ratio, and further ligated to BbsI-digested pDonor, then transformed in TOP10 cells and plated on kanamycin selection plates (Figure 1A). Bacterial clones with 5-fold more than paired guide RNAs were selected to confirm the representation of paired guide RNAs in the pool cloning by Sanger sequencing. Target-specific paired guide RNAs were identified based on Sanger sequencing. Guide RNAs were further efficiently shuttled into DEST containing lentiviral CAS9 expression plasmids using LR Gateway reactions depending on experimental needs (Figure 1A).

[0149] Lentivirus production, infection, and knockout Viral particles were generated by co-transfection of lentiviral expression plasmids (containing paired gRNA and wild-type CAS9 derivatives) with packaging plasmids (1:2:3 plasmid ratio) in the Lenti-X cell line using Xfect polymer (1:0.5 ratio) in 6-well plates. Viral supernatants were collected 72 hours post-transfection, filtered using a 0.45 μm filter, and then concentrated using a LentiX concentrator (Takarabio). Cells were transduced in the presence of 8 μg / ml polybrene using a multiplicity of infection (MOI) of 10 and centrifuged at 2200 g for 1 hour at 22 °C. For single-cell cloning to identify productive knockout clones, cells were directly sorted in round-bottom 96-well plates using constitutively expressed GFP 5 days post-infection. Single cell clones were expanded for 2 weeks, and 90% of the expanded cells from the 96-well plate were transferred to a new V-shaped 96-well plate, pelleted by centrifugation, and then the cell pellet was lysed with 50 mM NaOH at 96 °C for 30 min, followed by neutralization of the NaOH by addition of 10% 1M Tris-Hcl (PH: 8.0). The plate was centrifuged at 4.5K for 5 min, and the supernatant containing genomic DNA was collected and used for validation of gene editing by PCR amplification. To validate the editing, the targeted regions were amplified using specific primer sets and sequenced. Based on Sanger sequencing, at least two clones that were edited for each target gene were selected to validate the loss at the protein level using Western blotting (see also Figure 1A and Figure 8C).

[0150] Western blotting Multiple selected potential KO clones for each factor were analyzed for protein loss upon CRISPR-Cas9-mediated editing (see also Figure 8C). Protein lysates from 50,000 lysed cells in RIPA (50 mM Tris, 7.4, 1% NP-400.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, supplemented with protease inhibitors) buffer were loaded into each well of a 10% 12-well PAGE, resolved, and transferred onto a PVDF membrane. Membranes were blocked with 5% milk / BSA and proteins were detected with factor-specific antibodies (NF-κB1 p105 / p50 (D7H5M) rabbit mAb #12540, NF-κB2 p100 / p52 antibody #4882, and RELB RelB (C1E4) rabbit mAb #4922) (Cell Signaling), c-Rel antibody sc-71 (Santa Cruz biotechnology), NF-KB p65 antibody (C-20):sc-372 (Santa Cruz biotechnology) and HRP-linked secondary antibodies (anti-rabbit / mouse IgG, #7074 / 7076 (Cell Signaling)).

[0151] Detection of TLR stimulation and cytokines Cells were cultured in RPMI supplemented with 10% FCS, L-glutamine (2 mM), penicillin (100 U / ml), streptomycin (100 mg / ml), and sodium pyruvate at 37°C (5% CO2). On the day of stimulation, cells were seeded in duplicate in 12-well plates (1x106 / ml) and rested for 2 hours. After 2 hours, cells were stimulated with 0.5 μg / ml LPS (InvivoGen, LPS-EB (LPS from E. coli O111:B4)). 6 hours after stimulation, cells in the first set were lysed in 1 ml Trizol / well for RNA isolation, stimulation of the second set was continued for 24 hours, supernatants were collected, and LPS-induced cytokines (IL-6 and IL1-β) were analyzed using a Ready-SET-Go Elisa Kit (eBioscience).

[0152] RNA extraction and RNA sequencing Total RNA was extracted from bulk cells in a two-step RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction (TRIzol, Thermo Fisher Scientific, Waltham, MA, USA), and the aqueous phase was processed using the Qiagen RNeasy Micro clean-up procedure (Qiagen, Hilden, Germany). Purified RNA samples were quality checked using the Agilent RNA6000Pico assay (Agilent Technologies, Paolo Alto, CA). Reverse transcription and amplification were performed according to established methods. Briefly, cDNA was synthesized from 2 ng of purified total RNA using modified oligo(dT) primers and 1 μl of a 1:50,000 dilution of ERCC RNA spike in control (Ambion® ThermoFisher Scientific). 13 cycles of PCR amplification were performed to generate sufficient amounts of cDNA for downstream library preparation steps. The quantity and integrity of cDNA was assessed using a DNA high sensitivity reagent kit, Perkin Elmer LabChip GX (PerkinElmer, Waltham, MA, USA). Pooled cDNA libraries were then prepared (250 pg cDNA per sample) using a Nextera XT kit with dual indexes for demultiplexing (Illumina, San Diego, CA, USA). Libraries were quantified by qPCR (Kapa Biosystems, Wilmington, MA) to confirm loading concentration. Samples were subjected to 2x151 cycles of indexed PE sequencing runs on an Illumina HiSeq 4000.

[0153] RNA sequencing data analysis Reads obtained from Illumina sequencing were assessed for quality using FASTQC version 0.11.7. Salmon version 0.11.3 was used for quasi-mapping-based quantification of transcript abundance from paired-end reads, where a reference set of human transcripts was obtained from Gencode version 29. Transcript-level counts generated by Salmon were collapsed into gene-level counts using the tximportR / Bioconductor package version 1.2.3. Gene counts were imported into DESeq2 for analysis of differentially expressed genes (DEGs). A negative binomial generalized linear model (GLM) was fitted to the count data, which included coefficients modeling the effects of tissue type (CTR / c-Rel-KO / p50-KO / p52-KO / p65-KO / RelB-KO), treatment (untreated / LPS), and sample batch (one of three batches of the experiment in which the sample was treated). The size coefficient and variance parameters of the GLM were estimated from the count data. Counts were adjusted by the median ratio method to normalize for library size. Wald tests were performed on the model coefficients to identify DEGs. DEGs were selected to meet the following three criteria: nominal p-value < 0.005, at least 1.5-fold change, and baseMean (average count of all samples after library size normalization) > 10. Biological pathways and functions enriched in DEGs were analyzed using Ingenuity Pathway Analysis® (IPA). Custom scripts were written in R to perform Principal Component Analysis (PCA) and to analyze correlations between samples. In these analyses, normalized gene abundance was expressed as log transformed transcripts per million mapped reads, log2(TPM+1.0), where a pseudocount of 1.0 was added to prevent negative values, and only genes (n=12,845 genes) with baseMean> 10 and Entrez gene ID and gene name were used. The R package FactoMineR was used for PCA and pheatmap was used to plot the heatmaps.Sample correlation was assessed by Spearman correlation using the cor.test function in the R base library.

[0154] Analysis of ChIP-ChIP data To analyze the binding of NF-kB transcription factor to the promoters of differentially expressed genes, data from a previous NF-kB ChIP-ChIP experiment in U937 cells were obtained from ArrayExpress with accession ID E-WMIT-6. Raw two-color microarray data were processed using the marrayBioconductor package in R for background correction and intra-array normalization by the loess method. The resulting signal intensities were quartile normalized across all arrays in the dataset. The final ChIP signal intensity was calculated as the average of triplicate measurements.

[0155] Bioenergetics assay Metabolic assessment by extracellular flux analysis: analysis of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). Utility plates (Research Instrument) were hydrated overnight with sterile water in a 37°C non-CO2 incubator. A 50 ml Falcon tube containing 20 ml of calibration buffer was also incubated overnight in a 37°C non-CO2 incubator. The following day, U937 control and p65 -KO Cells (1x106 / ml in complete medium) were seeded into each well of a 12-well plate for 6 h, and after 6 h of incubation, OCR and ECAR were measured using an XFp analyzer (Agilent Seahorse Technologies). XFp Seahorse plates were seeded with 200,000 U937 control and p65-KO cells per well of poly-L-lysine-coated cell culture plates (Sigma). Culture medium was replaced with XF basal medium (Agilent Seahorse Technologies) supplemented with 2 mM glutamate, 2 mM sodium pyruvate, and 11 mM glucose, and pH adjusted to 7.4. Cells were then incubated at 37°C, 5% CO2 for 1 h.

[0156] Four compounds from the XFp Cell Mito Stress Test Kit (Agilent Technologies) were injected during the assay at the following final concentrations: oligomycin (1.5 μM), p-trifluoromethoxyphenylhydrazone (FCCP, 0.5 μM), and a mixture of antimycin A (0.5 μM) and rotenone (0.5 μM). The increase in OCR after FCCP application reflects the spare respiratory capacity (SRC) of the cells, i.e., the maximum achievable respiration rate. The ECAR rate was verified using a glycolysis stress test kit (Agilent Seahorse Technologies). The assay medium of the glycolysis stress test kit was supplemented with 2 mM glutamate only. After manual injection of 10 mM glucose, 1 μM oligomycin was added, followed by 50 mM 2-deoxyglucose. The injection of glucose into the previously glucose-free medium allowed the correlation of the increase in ECAR with the increase in glycolysis rate. After application of oligomycin, the glycolytic capacity of the cells, i.e., the maximum achievable glycolysis rate, can be calculated. Agilent Seahorse Software Wave 2.3 was used for data analysis. The Seahorse XF Cell Energy Phenotype Test Report was generated by Wave 2.3 report generator using the Seahorse XF Cell Mitochondrial Stress Test assay result data.

[0157] Methylcellulose Human Colony Forming Unit (CFU) Assay The day before plating cells for CFU, MethoCult Optimized Medium (STEMCELLS technologies) without EPO was transferred from -20°C to 2-8°C. U937 control and p65 - / - Cells (1 × 10 in complete medium 6100μl (500 cells / ml) were seeded into each well of a 12-well plate for 6 hours. After 6 hours of incubation, cells were washed with IMDM containing 25mM HEPES (washing medium) and resuspended at 5x103 / ml cells to make a 10x cell suspension for untreated cells or stimulated with 20ng / ml IL-6 for 12 hours and then washed and resuspended in IMDM containing 25mM HEPES (washing medium) to make a 10x cell suspension. Thawed MethoCult™ medium was shaken vigorously for 1-2 minutes and then left for at least 5 minutes until all air bubbles rose to the top before dispensing. Aliquots were prepared in MethoCult™ medium to 14mL using a 16 gauge blunt needle. 100μl (500 cells or 1000 cells) of cell suspension / plate was added directly to a tube of pre-dispensed complete MethoCult™ medium and mixed gently to make a homogenous cell suspension. 1.1 ml of cell suspension in MethoCult was plated in triplicate onto 35 mm dishes for each KO clone and incubated for 10 days at 37°C, 5% CO2, and ≥95% humidity. Colonies were scanned using an EVOS M7000 (Thermo Fisher Scientific) and manually counted.

[0158] shRNA knockdown U937 cells and p65 -KOKnockdown of ATP13A2 in cells was performed using a pLKO-based shRNA strategy (Figure 17), transduced with lentiviral shRNA pLKO vector. Transduced cells were selected with 1g / ml puromycin for 10 days. shRNA knockdown efficiency was verified using qPCR RNA isolation and quantitative RT-PCR (qRT-PCR). Total mRNA from cells was isolated using RNeasy Mini Kit (Qiagen) and reverse transcribed according to the manual instructions (BIO-RAD; #1708891). Real-time PCR was performed on an AB Biosystem 7000 using 10 ng of cDNA and oligonucleotide primers (300 nmol / L) (primer sequences are shown in Table 2). The following PCR conditions were used in a Light Cycler: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min in a 15 μl reaction. [Table 2] TIFF2024544003000003.tif48159

[0159] Immunofluorescence staining and analysis Cells were collected in 96-well plates for staining. Briefly, cells were washed once with PBS and then fixed in 4% PFA for 15 min at RT. Cells were permeabilized with 0.1% Triton X-100 for 10 min, washed with PBS, and then blocked with 3% BSA 0.1% Triton X-100 for 1 h. After blocking, cells were washed with PBS and further stained with antibodies in blocking buffer containing specific antibody dilutions (LAMP1 (1:250), TFEB (1:250), pTFEB (1:250)) overnight with slow rotation. Cells were washed three times with PBS and incubated in anti-rabbit AF647 (1:500) or anti-mouse AF594 (1:500) diluted in blocking buffer for 1 h at room temperature. Cells were washed three times and stained with Hoescht dye (1:1000) in PBS for 15 min. Cells were washed and loaded into poly-L-lysine-coated Ibidi chambers for visualization with an Olympus confocal system. The mean fluorescence intensity of LAMP1 was calculated using Image J software by manually selecting 100 cells / group (number of fields per group = 3).

[0160] AML xenograft trials All AML xenograft experiments were performed as outlined in Figure 12A and Figure 13A. NOG mice (4-6 weeks old) were sublethally X-irradiated (1.2 Gy) 2 days prior to transplantation. GFP+CTR and p65-KOU937 cells were injected into mice via the tail vein in a final volume of 100 μL PBS (2 × 10 6 Humanized NOG (huNOG) mice were generated by sublethal X-ray irradiation (1.2 Gy) of 7-8 week-old NOG mice, followed by transfection with 50,000-60,000 CD34 cells / mouse. + Human umbilical cord blood-derived HSCs were generated by tail vein injection. Successful engraftment was assessed by the detection of hCD45 in peripheral blood at 4, 8, and 12 weeks after human HSC transplantation. + Cells vs. mCD45 +The results were confirmed by flow cytometric analysis of the cells. 12-14 weeks after human HSC transplantation, mice were sublethally irradiated and 2 days later U937 cells were injected as described for NOG xenografts. Mouse weights were recorded daily. On days 5-7 and 11-16 after AML cell injection, peripheral blood was collected from the retro-orbital sinus using heparinized capillary tubes (MARIENFELD) for xenograft analysis. At termination, the inventors of the present disclosure collected BM. Phenotypic analysis of xenografts in blood and BM was performed as described in the flow cytometry section.

[0161] histopathology Mice were euthanized, and bone marrow and spleen tissues were harvested and fixed in 10% neutral buffered formalin (Sigma Aldrich, #HT501128) at room temperature for more than 48 hours. Femoral tissues were then decalcified with Osteo Soft (Merck, USA) and periodically cut and processed for histological evaluation. Sections were cut at a thickness of 5 mm and stained with H&E. Tissues were then observed under an Olympus BX53 upright microscope, and photographs were taken with an Olympus DP71 digital camera using an Olympus DP controller and DP manager software (Olympus Life Science, Japan). Pathological evaluation was performed according to subjective scoring as follows: no lesion: 0, minimal: 1, mild: 2, moderate: 3, marked: 4, severe: 5.

[0162] Flow cytometry Anti-human antibodies for flow cytometry used in the experiment were hCD45-PerCP-Cy5.5 (ThermoFisherScientific); hCD44-BV650, hCD117-BV785, hCD33-APC, hCD244-PE-CY7 (eBioscience); mCD45-APC-Cy7, hCD45RA-EF450 (BioLegend); hCD34-PE, hCD123-BUV395 (BD Bioscience). Whole blood staining was performed with RBC lysed cells using ACK buffer (1xRBC lysis buffer, ThermoFisher Scientific) for 5 min at room temperature, followed by washing with PBS. RBC lysed blood cells were stained with live-dead (L\D) stain (UV1:500, Thermo Fisher Scientific) for 30 min. Cells after L\D staining were washed once with FACS buffer (PBS, 2% FCS, 1 mM EDTA, 0.1% sodium azide) and further stained with antibody cocktail in FACS buffer containing specific antibody dilutions [hCD45-PerCP-Cy5.5 (1:50), hCD44-BV650 (1:40), hCD33-APC (1:10), hCD117-BV785 (1:20), hCD244-PE-CY7 (1:20), mCD45-APC-CY7 (1:100), hCD45RA-EF450 (1:30), hCD34-PE, (1:10), hCD123-BUV295 (1:25)] for 15 min at 40 °C in the dark. Cells were washed once with FACS buffer and acquired using an LSRII-5 laser (BD Bioscience). Flow cytometry data were analyzed using FlowJo (version 10.4, TriStar). The overall gating strategy is outlined in Figures 13B-14A.

[0163] Survival analysis of genes regulated by p65-p65 dimers in AML datasets Gene expression and survival data were obtained from cBioPortal for the AML datasets TARGET and TCGA. Only patients who received standard chemotherapy without BM transplant were selected, and PML-RAR samples were also excluded from the analysis due to their interaction with p65. Univariate Cox regression analysis was performed for 374 (out of 441) genes regulated by p65 in each of the two datasets. A random effects model meta-analysis of hazard ratios was then performed to obtain a combined hazard ratio represented as a forest plot. The meta-analysis revealed a list of 29 genes from which panels of three or four possible all genes were constructed. Each of these panels was then used in a multivariate Cox regression analysis for each of the three datasets to determine the predictive performance of the panels as indicated by the likelihood ratio test P value. A rank sum approach was then used to rank the panels using the results of the three datasets and the combined P value calculated using the Fisher method. Analyses were performed in R version 3.6.2 using the survival and metafor packages for Cox regression analysis and meta-analysis of hazard ratios, respectively.

[0164] statistical analysis All values ​​are the mean ± SD or SEM of individual samples. Data analysis was performed using R version 3.6.2 or GraphPad Prism software (GraphPad Software Inc., version 7.01). Statistical tests used are indicated in the respective sections and figure legends.

[0165] Accession code The GEO accession number for the RNAseq data generated in the disclosed study is GSE153158.

[0166] Exemplary embodiments of the present disclosure will be better understood and readily apparent to those skilled in the art upon reading the following description in conjunction with the figures, where applicable. The exemplary embodiments are not necessarily mutually exclusive, and some embodiments may be combined with one or more embodiments to form new exemplary embodiments. The exemplary embodiments should not be construed as limiting the scope of the disclosure. [Brief description of the drawings]

[0167] [Figure 1A] A diagram outlining the generation of p50, p52, p65, c-Rel, and RelB KO in U937 cell lines using an oligomer-based pgRNA approach is shown (see also Figures 8 and 18A). [Figure 1B] Heatmaps of functional validation of KO cells upon LPS stimulation. Analysis of induced IL-6 and IL-1β secretion in culture supernatants. Data from one experiment out of two performed in triplicate are shown. Heatmaps show functional impact of loss of NF-κB TFs: p50, p52, p65, c-Rel and RelB in AML cells. AML U937 cells were assessed for potential loss of cellular function by analysis of LPS-mediated induction of inflammatory proteins. Impaired induction of IL-6 and IL-1β proteins was found in all KO clones of p50, p52, p65 and c-Rel upon LPS stimulation, whereas no impact was observed in RelB-KO clones compared to unedited control cells (CTRL). Overall, this indicates loss of NF-B TF-related cellular functions, namely the inflammatory response to LPS, known to be mediated via NF-κB TFs. This defect was due to loss of the target protein in the NF-B TF KO clone (Fig. 8C ). [Figure 1C] The left panel shows a schematic representation of the RNA-seq analysis for NF-kB TF KO cells, and the right panel shows the PCA analysis for 12845 genes (see also Figure 9).UT - untreated cells, LPS - LPS treated cells, CTR - control unedited cells. [Figure 1D]A Venn diagram showing the number of DEGs observed in LPS-stimulated NF-kB KO versus unstimulated NF-kB KO and CTR cells is shown. [Figure 1E] A Venn diagram showing the number of DEGs observed in unstimulated cells, NF-kB Ko versus CTR is shown. [Figure 1F] A heatmap of Spearman rank correlations between independent clones of factor-specific NF-kB KO based on the total set of LPS-related DEGs is shown. Spearman correlation analysis based on the LPS-related 430 DEGs indicated homogeneity between independent KO clones since their correlations were the highest, and also identified two major functional aspects of NF-kB represented by the canonical cluster (middle bottom right, p65-KO, p50-KO, c-Rel-KO, and p52-KO clones) and the non-canonical cluster (top left, RelB and CTR clones). Overall, this indicates that canonical NF-kB TFs are the main drivers of LPS-induced inflammatory responses compared to the non-canonical NF-kB TF; RelB. [Figure 1G] Heatmap of LPS-associated DEGs from Ingenuity pathway analysis (IPA) is shown. IPA of LPS-stimulated DEGs showed a marked reduction in the ability of p50-KO, p52-KO, p65-KO, and c-Rel-KO cells to induce activation of inflammatory pathways including TLR, TNFR2, and IL-6 signaling in response to LPS. However, in RelB-KO cells, inflammatory pathways were only moderately affected and responded in a manner almost identical to that seen in CTR cells. Overall, this further indicates that canonical NF-kB TFs are the main drivers of LPS-induced inflammatory responses compared to the non-canonical NF-kB TF; RelB. Color gradations in the heatmap represent significant changes (-log10p) in the expression of pathway-associated genes. -log10p>1.33 was considered significant, and Z-scores represent the directionality of the pathway. + indicates increased activity, - indicates decreased activity, and no symbol indicates no prediction by IPA. [Figure 1H]Heatmap with Spearman rank correlation between independent clones of factor-specific NF-kB KO based on the total set of DEGs in unstimulated cells. Spearman correlation analysis based on 1258 DEGs showed homogeneity among independent KO clones since their correlation was highest among all KO clones. Correlation analysis also captured known functional interactions between RelB clones and p65-KO clones since those independent KO clones clustered together. [Figure 1I] Heatmap from IPA analysis of unstimulated DEGs is shown. IPA analysis of unstimulated DEGs in different NF-κB-KO cells showed enrichment of metabolic and cancer pathways, which were over-represented in p65-KO cells. Taken together, global gene expression analysis of NF-κB KO human AML cell line U937 suggests state-specific homogeneity and heterogeneity between transcriptional regulation by NF-κB family TFs. Color gradation in heatmap represents significant changes (-log10p-value) in expression of pathway-associated genes. -log10p-value >1.33 is considered significant and Z-score represents the directionality of the pathway. + indicates increased activity, - indicates decreased activity and no symbol indicates no prediction by IPA. [Figure 2A] Heatmap showing identification of p65 homodimer-regulated target genes in DEGs from unstimulated NFkB KO vs. CTR. DEGs were integrated with ChIP-ChIP binding profiles to identify 595 overlapping genes. Module analysis identified a p65-p65 homodimer-specific module containing 225 genes (downregulated modules containing p65 are indicated by light grey boxes with - symbols and upregulated modules are indicated by dark grey boxes with + symbols). [Figure 2B]Enrichment analysis of disease functions within 225 p65-p65 homodimer-specific DEGs by IPA analysis. Metabolic and cancer-related pathways remained significantly enriched in IPA analysis of p65 homodimer-specific DEGs (225 genes), further reinforcing the potential role of p65 homodimer in regulating key aspects of metabolism and cancer. Color gradation in the heatmap represents significant changes (-log10p value) in the expression of pathway-related genes. -log10p>1.33 was considered significant, and Z-score represents the directionality of the pathway. + indicates increased activity, - indicates decreased activity, and no symbol indicates no prediction by IPA. [Figure 2C] Heatmap showing the expression of genes related to metabolic pathways from IPA across NF-kB KO and CTR cells. p65 deficiency induced deregulation of metabolic pathways such as OXPHOS, Sirtuin signaling pathway, and mitochondrial dysfunction in AML cells was further highlighted by distinct regulation of genes involved in these pathways in p65-KO cells compared to CTR and other NF-B KO cells. This further suggests p65-mediated regulation of metabolic pathways in U937 AML cells. [Figure 2D] Genome browser shots are shown plotting the binding patterns of NF-kB TFs across the AKT1 and COX6A1 loci (lower panel) and their respective RNA-seq reads in KO and CTR cells (upper panel). [Figure 2E] Shown are plots of MitoStress analysis of mitochondrial function using Oxygen Consumption Rate (OCR) for OXPHOS. Binding data for N=4 clones for both p65 KO and CTR are shown. [Figure 2F] FIG. 2C shows graphs depicting individual OXPHOS parameter data from FIG. 2E. [Figure 2G] Plots of glycolytic stress analysis of extracellular acidification rate (ECAR) versus lactate production for p65- / -KO and four CTR clones are shown. [Figure 2H]FIG. 2C is a graph showing individual glycolysis parameter data from FIG. 2G. [Figure 2I] Plots of cellular energy phenotyping using OCR and ECAR measurements in the mitochondrial stress test are shown, demonstrating a high "hybrid" energy state in p65-KO clones. Data from F and H are mean ± SD, *, P < 0.05, Mann-Whitney test. [Figure 3A] Heatmap of mRNA expression of p65 homodimer-regulated genes related to cancer pathways across NF-κB TF KO and CTR. p65 deficiency induced deregulation of cancer pathways including AML and AML-associated signaling pathways such as IL-6, IL-7, CXCR4, JAK-STAT, and GM-CSF signaling in AML cells was highlighted by distinct regulation of genes involved in these pathways in p65-KO cells compared to CTR and other NF-B KO cells. This further suggests a potential inhibitory role of homodimeric p65 in regulating leukemia-specific pathways. [Figure 3B] Shown are images (left panel) and graphs (right panel) of compiled data showing CFU analysis of p65-KO and CTR clones (N=5 clones) and frequency of total colonies formed per 500 cells. [Figure 3C] FIG. 1 shows a schematic diagram of inducible AML xenografting in huNOG mice. [Fig. 3D-E] Graphs of weight loss and Kaplan-Meier survival curves are shown for huNOG mice receiving either p65-KO cells or CTR U937 cells, respectively (N = 15–17 mice in each group, data from two experiments). [Figure 3F] Flow cytometry dot plots from blood and tissue (BM and spleen) analysis of CTR or p65-KO induced xenograft expansion in huNOG mice. hCD45+GFP+ AML cells are indicated by boxes. [Figure 3G]Graph showing compiled data of blood flow cytometry analysis of CTR or p65-KO induced xenograft expansion in huNOG mice, on average 8 and 13 days post-injection, in two different experiments. [Figure 3H] Graphs of BM and spleen flow cytometry analysis of CTR or p65-KO induced xenograft expansion in huNOG are shown. [Figure 3I-J] Plots of correlation analysis of xenograft expansion (GFP+ AML cells in blood) and humanization (i.e., chimerism in blood) with survival prior to CTR or p65-KO xenograft induction in huNOG mice are shown. [Figure 3K] 13 shows a graph showing a comparison of total blood human CD45+ cells in control and p65-KO xenografts in huNOG mice. [Figure 3L] FIG. 1 shows plots of correlation analysis of xenograft expansion (hCD45+GFP+ cells) and normal hematopoiesis (hCD45+GFP- cells) in blood in huNOG mice injected with CTR cells or p65-KO AML cells. [Figure 4A] A schematic diagram of analysing AML patient data using 441 p65-specific DEGs is shown (Cox regression results for datasets TARGET and TCGA, left panel). The top genes from the meta-analysis of genes regulated by p65 / p65 homodimers are shown in tabular form (right panel). [Figure 4B] Figure 1 shows forest plots showing hazard ratios and 95% CIs (confidence intervals) for ATP13A2 from univariate Cox regression analysis in the TARGET and TCGA datasets. Meta-HRs (hazard ratios) and CIs are shown. [Figure 4C] 1 shows Kaplan-Meier curves for ATP13A2 as a genetic predictor for stratifying survival of AML patients. [Figure 4D]Images and CFU analysis graphs (left panels) of p65-KO cells (N = 5 clones), CTR cells (N = 5 clones), and p65-KO-shATP13A2 cells (n = 3) clones are shown, as well as compiled data showing the frequency of total colonies formed in 500 cells (right panels). [Figure 4E] Schematic diagram of p65-KO, CTR, and p65-KO-shATP13A2-induced AML xenograft experiments in huNOG mice. [Figure 4F] Graphs showing blood and tissue (BM and spleen) flow cytometry analysis of p65-KO, CTR, and p65-KO-shATP13A2 induced xenograft expansion in huNOG mice. [Figure 4G] Kaplan-Meier survival curves of huNOG mice receiving either p65-KO, CTR, and p65-KO-shATP13A2 are shown (N=5 mice per group). [Figure 4H] H&E staining of BM of p65-KO, CTR, and p65-KO-shATP13A2-induced xenografts in huNOG mice. Magnification - 20x and 60x. Normal bone marrow (left panel of placebo group) shows the presence of myeloid (Ms), erythroid (Es), and megakaryocyte (Mg), sinusoidal (S) intertwining within hematopoietic cells. Infiltrated AML cells are indicated by black arrows. Right panel shows overall pathological score. [Figure 4I] H&E staining of spleens from huNOG mice receiving p65-KO, CTR, and p65-KO-shATP13A2-induced xenografts. Magnification - 20x and 100x. Images show normal spleens (left panel of placebo group), which contain white pulp (WP), red pulp (RP), and EMH (left panel). Infiltrated AML cells, indicated by asterisks, and apoptosis (black arrows) are shown in spleens from huNOG mice bearing xenografts. Right panel shows overall pathological score. [Figure 5A]Gene signature enrichment analysis (GSEA) of 441 p65-KO specific DEGs is shown, showing enrichment in the KEGG_Lysosomal pathway. Expression of selected genes in control and p65-KO cells is shown at the bottom as a heatmap. The heatmap shows the expression of each gene in three individual p65-KO and CTRL clones. [Figure 5B] Histogram overlay plots showing the mean fluorescence intensity (MFI) of pTFEB (left panel) and TFEB (right panel) proteins in p65-KO, p65-KO-shATP13A2, and CTR cells as assessed by flow cytometry. Compiled data from each of the three clones are shown at the bottom as bar graphs. [Figure 5C] Immunoblots showing protein expression of pTFEB, TFEB, and GAPDH in control, p65-KO, p65-KO-shATP13A2, and CTR cells are shown. [Figure 5D] Histogram overlay plots of mean fluorescence intensity (MFI) of intracellular LAMP1 are shown (left panel). Bar graphs (right panel) represent the MFI of three clones from each group of p65-KO cells, p65-KO-shATP13A2 cells, and CTR cells measured by flow cytometry. [Figure 5E] Immunofluorescence staining and confocal microscopy analysis of LAMP1 in p65-KO, p65-KO-shATP13A2, and CTR cells (representative images, left panel). The right panel shows the aggregate data of MFI per cell (100 cells / group) analyzed by ImageJ software. [Figure 5F] Histogram overlay plots (left panel) of lysotracker MFI in p65-KO, p65-KO-shATP13A2, and CTR cells measured by flow cytometry. The right panel shows compiled MFI data in a bar graph. [Figure 5G]Figure 1 shows a graph of mitochondrial function mitochondrial stress analysis using oxygen consumption rate (OCR) for OXPHOS measured using a Seahorse analyzer. Binding data for N=3 clones for all three groups: p65-KO, p65-KO-shATP13A2, and CTR are shown. [Figure 5H] FIG. 1 shows a graph of glycolytic stress analysis of extracellular acidification rate (ECAR) measured using a Seahorse analyzer for lactate production in all three cell types. [Figure 5I] Graphs of individual glycolysis parameter data from FIG. 5H are shown. [Figure 5J] Graphs of cellular energy phenotyping using OCR and ECAR measurements on Mito stress test data from 5G and 5I are shown, demonstrating a high "hybrid" energy state in p65-KO clones. [Figure 5K] A schematic of the CTR and shATP13A2-induced AML xenograft experiment in huNOG mice (left panel) is shown. The right panel is the Kaplan-Meier survival curve of huNOG mice receiving control or shATP13A2 cells (N = 5–6 mice / group). [Figure 6A]Heatmaps depicting the levels of human cytokines and chemokines in the serum of xenografts of control cells and p65-KO U937 cells (samples from huNOG mice in Figure 3E). Cytokines / chemokines that were significantly modulated across control and p65-KO xenograft groups (n=6 mice per group) are indicated by * (Student's t test). Analysis of human cytokines and chemokines was performed using Luminex assays in serum from huNOG xenografts. The heatmaps showed that several cytokines / chemokines, such as MDC (CCL22), IL-10, IL-5, IP-10, and PDGF-AA, were significantly modulated in the serum of p65-KO xenografts compared to huNOG mice receiving control xenografts. MDC and IL5 were increased, and IL-10, IP-10, and PDGF-AA were decreased. Taken together, these data suggest an anti-leukemic effect of p65, where reduction of p65 has an impact on normal hematopoiesis via a competitive advantage of p65-KO AML cells and also induces a pro-leukemic cytokine signature in xenografts. [Figure 6B] Bar graphs of key regulated cytokines in p65-KO induced xenografts compared to controls in Figure 6 A. *, P<0.05, **, P<0.01, Student's t test. [Figure 7A] Histological images of analysis of pathological changes at 20x and 60x by H&E staining of BM from huNOG mice injected with either control AML cells (left panel, n=5), p65-KO AML cells (middle panel, n=5), or p65-KO-ATP13A2-KD AML cells (right panel, n=4) are shown. Necrosis (N), evident by the presence of pyknotic nuclei (arrows), is shown. Affected areas are hypocellular and replaced by amorphous granular eosinophilic material (#), often accompanied by hemorrhage (*). The graph on the right shows the total pathological score based on a subjective score of necrosis and hemorrhage. [Figure 7B]Figure 7B shows histological images of induced pathological changes in the spleen of the mice (20x magnification), showing lymphodepletion in the p65-KO xenografts (see areas marked by black boxes) compared to intact lymphoid areas in control xenografts (injected with CTR AML cells) or in p65-KO-shATP13A2 xenografts (injected with p65-KO-shATP13A2 AML cells). The white pulp area (WP) is marked by a black box and infiltrated AML cells are indicated by arrows. [Figure 7C] Heatmaps depicting normalized levels of human cytokines and chemokines in plasma of mouse xenografts in A are shown. Cytokines / chemokines significantly modulated across control (n=9), p65-KO (n=8) and p65-KO-ATP13A2-KD (n=8) xenograft groups are indicated by * (one-way ANOVA). Analysis of human cytokines / chemokines demonstrated a reduced inflammatory state in huNOG mice receiving ATP13A2-depleted p65KO AML cells. Importantly, trends in CCL22, IL10, IL1RA, PDGF-AA, FLT3-G, VEGF, analytes known to be associated with AML pathology and reduced survival in AML patients, were reversed in serum of huNOG mice receiving ATP13A2-depleted p65KO AML cells. This reversal was consistent with the reversal of lymphocyte depletion (Figure 7B). Taken together, our data link the aggressive nature of p65-KO cells to a proleukemogenic cytokine and chemokine signature, as well as immune suppression driven via ATP13A2. [Figure 7D] Bar graphs showing significantly reversed p65-KO associated cytokines / chemokines in p65-KO-ATP13A2-KD xenografts. P values, one-way ANOVA. [Figure 8A] Schematic diagram of exons targeted in NF-kB TF genes by pgRNA CRISPR-Cas9 approach. The first five exons of NFKB1, NFKB2, RELA, REL, and RELB genes are shown. [Figure 8B]Shown is a sequencing plot with PCR amplification using gene-specific primers and verification of editing in the targeted regions by Sanger sequencing. [Figure 8C] 1 shows immunoblots verifying protein loss in identified edited clones of NF-kB TF by Western blotting. Each clone identified, verified, and selected for further experiments is marked by a letter in a rectangular box. [Figure 9] 1 shows the workflow used to analyze the RNA-seq data. [Figure 10] Volcano plots showing differential gene expression in LPS stimulated and unstimulated KOs are shown. The volcano plots show the significance and fold change of genes in differential gene expression analysis between various clones. Both untreated (UT) and LPS treated conditions are shown. Genes to the left and right of the dashed line (displayed as dots) represent up- and down-regulated genes, respectively, selected based on P-value <0.005 and log2 fold change >1.5. [Figure 11] Genome browser shots and plots of the binding patterns of NF-kB TFs across the IL-6R and PLCG2 loci (lower panels) and the respective RNA-seq reads at those loci in KO and CTR cells (upper panels) are shown. [Figure 12A] FIG. 1 shows a schematic diagram of the generation of U937-induced AML xenografts in NOG mice. [Figure 12B-C] Plots of weight loss and Kaplan-Meier survival curves of NOG mice receiving either p65-KO cells or CTR U937 cells are shown (N = 7–8 mice per group, data from two experiments). [Figure 12D]Dot plots with flow cytometry gating strategy and analysis of xenograft expansion in the blood of NOG recipient mice 11-16 days post-injection, and blood flow cytometry analysis of xenograft expansion induced by CTR or p65-KO in NOG mice 11-16 days post-injection. hCD45+GFP+AML cells are shown in green. [Figure 12E] Kaplan-Meier survival curves of NOG mice receiving either p50-KO cells, p52-KO cells, c-Rel-KO cells, RelB-KO cells, or CTR U937 cells are shown (N = 4–5 mice / group, except for RelB). Survival curves for the RelB and CTR groups are based on three experiments (N = 13–14 mice per group). [Figure 13A] FIG. 1 shows a schematic diagram of the generation of a U937-induced AML xenograft model in huNOG mice. [Figure 13B] Flow cytometry gating strategy and analysis of xenograft expansion in blood, BM, and spleen of huNOG recipient mice at days 11-16 post-injection. [Figure 14A] Flow cytometry gating strategy and analysis of xenograft expansion in the blood of huNOG recipient mice at days 11-16 post-injection. Analysis of cell phenotype (expression of hCD123, hCD117, hCD244, hCD45RA) of expanded xenografts in blood (hCD45+GFP+ cells) is shown by histogram overlay plots. [Figure 14B] Shown is data analyzed as in Figure 14A for cell phenotype of expanded xenografts in blood as shown by histogram overlay plots. Compiled data for each of the specific phenotypic markers in different huNOG mice are shown as bar graphs at the bottom. [Figure 15] 1 shows survival plots with signatures of three and four gene combinations of p65 / p65 homodimer-regulated genes that improve prediction of overall survival in the TCGA and TARGET cohorts. Gene combinations are indicated on top of each plot. [Figure 16A] A schematic diagram of shRNA knockdown in p65-KO cells showing shRNA sequences, cloning, infection and selection is shown. [Figure 16B] 1 shows a bar graph of qPCR validation of ATP13A2 knockdown in p65-KO cells. [Figure 17] FIG. 5C shows graphs of individual OXPHOS parameter data from FIG. 5G. [Figure 18A] The pAdaptor and pDonor plasmids used to generate pgRNA are shown. [Figure 18B] 1 shows a Gateway-compatible CRISPR / CAS9 expression plasmid, CAS9-T2AGFP, for knockout generation. [Figure 19] Schematic diagram of the proposed model showing the novel p65-ATP13A2-mediated control of AML development: The left box represents the sequence of events that occur when p65 is depleted in the AML cell line U937, which in turn leads to increased expression of lysosomal transporter ATP13A2. p65-deficient AML cells show deregulation of energy and lysosomal pathways, leading to exacerbation of AML pathology in xenograft humanized mouse models. The right box represents the sequence of events when ATP13A2 expression levels are reduced in p65-deficient AML cells, which leads to p65-mediated metabolic reprogramming in AML cells and reversal of pathology in humanized mice. Overall, the inventors of this disclosure propose that p65 deficiency exacerbates AML pathology through an ATP13A2-mediated mechanism involving metabolic adaptation and lysosomal dysfunction.

[0168] Purpose Embodiments of the methods disclosed herein provide methods of identifying therapeutic targets for treating acute myeloid leukemia (AML) using genetically modified cells and methods of treating acute myeloid leukemia (AML) in a subject in need thereof.

[0169] Advantageously, the present invention identifies ATP13A2 (also known as Park9) as a therapeutic target for AML.

[0170] More advantageously, the present invention provides for the development of clinical candidates against ATP13A2 for the treatment of AML.

[0171] More advantageously, the present invention provides for the development and use of ATP13A2 as a target for the treatment of AML.

[0172] More advantageously, the present invention provides for the development of targeted therapies for AML and combination therapies for AML (in combination with standard chemotherapy).

[0173] Those skilled in the art will appreciate that other variations and / or modifications may be made to the embodiments disclosed herein without departing from the spirit or scope of the disclosure as broadly described. For example, in the description herein, features of different exemplary embodiments may be mixed, combined, interchanged, incorporated, adopted, modified, subsumed, etc. among the different exemplary embodiments. The present embodiments are therefore considered in all respects to be illustrative and not restrictive.

Claims

1. A genetically modified cell, wherein at least one gene has been deleted from said cell, and said gene is selected from the group consisting of p65 (RELA), p50 (NFKB1), p52 (NFKB2), c-Rel (REL), and RelB (RELB).

2. 13. A method for identifying a therapeutic target for treating acute myeloid leukemia (AML) in a subject, the method comprising using a cell described in claim 1.

3. A method of treating acute myeloid leukemia (AML) in a subject in need thereof comprising modulating activity of the NF-KB pathway.

4. The method of claim 3, wherein the modulation of the NF-KB pathway modulates multiple pathways including metabolic pathways, inflammatory pathways, cancer-related pathways, and combinations thereof.

5. The method of claim 3, wherein the NF-KB pathway gene is p65.

6. The method of any one of claims 3 to 5, wherein the metabolic pathway comprises oxidative phosphorylation (OXPHOS), mitochondrial dysfunction, sirtuin signaling and / or mTOR signaling.

7. 7. The method of any one of claims 3 to 6, wherein the cancer associated pathways include pathways associated with acute myeloid leukemia (AML), small lung cancer, and / or pancreatic adenocarcinoma, and optionally, the cancer associated pathways include AML and AML associated signaling pathways including IL-6, IL-7, JAK, CXCR4, JAK-STAT, and / or GM-CSF.

8. The method of any one of claims 3 to 7, wherein the inflammatory pathway comprises TLR, TNFR2, CCL22, IL-10, IL-17A, CD40 and / or IL-6 signaling.

9. The method according to any one of claims 3 to 8, wherein the expression of genes and / or proteins of lysosome-associated proteins is modulated.

10. The method according to any one of claims 3 to 9, wherein the function of a lysosome-associated protein is regulated.

11. The method according to any one of claims 3 to 10, wherein the lysosome-associated protein is ATP13A2 / Park9.

12. The method according to any one of claims 3 to 11, comprising administering an agent that inhibits the activity of the ATP13A2 gene.

13. 13. The method of any one of claims 3-12, wherein the treatment reduces one or more symptoms including a decrease in oxygen consumption rate (OCR), a decrease in maximal respiration, a decrease in spare respiratory capacity, a decrease in non-mitochondrial respiration, and combinations thereof.

14. 14. The method of any one of claims 3 to 13, wherein the treatment reduces one or more symptoms including a reduction in glycolysis, a reduction in glycolytic capacity, a reduction in maximal mitochondrial respiration, and combinations thereof.

15. The method of any one of claims 3 to 14, wherein the treatment reverses or ameliorates a dysfunction in mitochondrial function.

16. The method of any one of claims 3 to 15, wherein the treatment reduces one or more symptoms including removal of the ability to proliferate and / or form colonies.

17. 17. The method of any one of claims 3 to 16, wherein the subject is further treated with an inhibitor comprising a chemotherapeutic agent, an immunotherapeutic agent, a cellular therapeutic agent, an oligonucleotide, an antigen binding molecule, a small molecule inhibitor, and / or a combination thereof.

18. 20. The method of claim 17, wherein the subject is further treated with a chemotherapeutic agent.

19. ATP13A2 inhibitors for use in therapy or medicine.

20. ATP13A2 inhibitors for use in treating AML.

21. Use of an ATP13A2 inhibitor in the manufacture of a medicament for treating AML.

Citation Information

Patent Citations

  • Compositions and Methods for Polynucleotide Transfection

    JP2016505620A

  • NF-KB p50 DEFICIENT IMMATURE MYELOID CELLS AND THEIR USE IN TREATMENT OF CANCER

    US20210260128A1